# Genome-wide analyses identify 21 infertility loci and over 400 reproductive hormone loci across the allele frequency spectrum

- 5 Samvida S. Venkatesh<sup>1,2</sup>, Laura B. L. Wittemans<sup>3,4</sup>, Duncan S. Palmer<sup>1,5</sup>, Nikolas A. Baya<sup>1,2</sup>,
- 6 Teresa Ferreira<sup>1</sup>, Barney Hill<sup>1,5</sup>, Frederik Heymann Lassen<sup>1,2</sup>, Melody J. Parker<sup>1,6</sup>, Saskia
- 7 Reibe<sup>1,5</sup>, Ahmed Elhakeem<sup>7,8</sup>, Karina Banasik<sup>9,10</sup>, Mie T. Bruun<sup>11</sup>, Christian Erikstrup<sup>12,13</sup>, Bitten
- 8 A. Jensen<sup>14</sup>, Anders Juul<sup>15,16</sup>, Christina Mikkelsen<sup>17,18</sup>, Henriette S. Nielsen<sup>19,20</sup>, Sisse R.
- 9 Ostrowski<sup>17,20</sup>, Ole B. Pedersen<sup>20,21</sup>, Palle D. Rohde<sup>22</sup>, Erik Sorensen<sup>17</sup>, Henrik Ullum<sup>23</sup>, David
- 10 Westergaard<sup>9,10</sup>, Asgeir Haraldsson<sup>24,25</sup>, Hilma Holm<sup>26</sup>, Ingileif Jonsdottir<sup>24,26</sup>, Isleifur Olafsson<sup>27</sup>,
- 11 Thora Steingrimsdottir<sup>24,28</sup>, Valgerdur Steinthorsdottir<sup>26</sup>, Gudmar Thorleifsson<sup>26</sup>, Jessica
- 12 Figueredo<sup>29</sup>, Minna K. Karjalainen<sup>30,31,32</sup>, Anu Pasanen<sup>33</sup>, Benjamin M. Jacobs<sup>34</sup>, Nikki
- 13 Hubers<sup>35,36</sup>, Genes & Health Research Team, Estonian Biobank Research Team, Estonian
- 14 Health Informatics Research Team, DBDS Genomic Consortium, FinnGen, Margaret
- 15 Lippincott<sup>37,38</sup>, Abigail Fraser<sup>7,8</sup>, Deborah A. Lawlor<sup>7,8</sup>, Nicholas J. Timpson<sup>7,8</sup>, Mette Nyegaard<sup>22</sup>,
- 16 Kari Stefansson<sup>24,26</sup>, Reedik Magi<sup>29</sup>, Hannele Laivuori<sup>30,39,40,41</sup>, David A. van Heel<sup>42</sup>, Dorret I.
- 17 Boomsma<sup>35,36</sup>, Ravikumar Balasubramanian<sup>37,38</sup>, Stephanie B. Seminara<sup>37,38</sup>, Yee-Ming
- 18 Chan<sup>38,43</sup>, Triin Laisk<sup>29</sup>, Cecilia M. Lindgren<sup>1,2,4,44</sup>
- 19
- 20 1. Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of
- 21 Oxford, Oxford OX3 7LF, United Kingdom
- 22 2. Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford,
- 23 Oxford OX3 7BN, United Kingdom
- 24 3. Novo Nordisk Research Centre Oxford, Oxford, United Kingdom
- 25 4. Nuffield Department of Women's and Reproductive Health, Medical Sciences Division,
- 26 University of Oxford, United Kingdom
- 27 5. Nuffield Department of Population Health, Medical Sciences Division, University of Oxford,
- 28 Oxford, United Kingdom
- 29 6. Nuffield Department of Clinical Medicine, University of Oxford, John Radcliffe Hospital,
- 30 Oxford, United Kingdom
- 31 7. MRC Integrative Epidemiology Unit at the University of Bristol, Bristol, United Kingdom
- 8. Population Health Science, Bristol Medical School, University of Bristol, Bristol, UnitedKingdom
- 34 9. Novo Nordisk Foundation Center for Protein Research, University of Copenhagen,
- 35 Copenhagen, Denmark
- 36 10. Department of Obstetrics and Gynecology, Copenhagen University Hospital, Hvidovre,
- 37 Copenhagen, Denmark
- 38 11. Department of Clinical Immunology, Odense University Hospital, Odense, Denmark
- 39 12. Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark

- 40 13. Department of Clinical Medicine, Health, Aarhus University, Aarhus, Denmark
- 41 14. Department of Clinical Immunology, Aalborg University Hospital, Aalborg, Denmark
- 42 15. Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of
- 43 Copenhagen; Copenhagen, Denmark
- 44 16. Department of Growth and Reproduction, Copenhagen University Hospital-Rigshospitalet,
- 45 Copenhagen, Denmark
- 46 17. Department of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet,
- 47 Copenhagen, Denmark
- 48 18. Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and
- 49 Medical Science, Copenhagen University, Copenhagen, Denmark
- 50 19. Department of Obstetrics and Gynecology, The Fertility Clinic, Hvidovre University Hospital,
- 51 Copenhagen, Denmark
- 52 20. Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of
- 53 Copenhagen, Copenhagen, Denmark
- 54 21. Department of Clinical Immunology, Zealand University Hospital, Kge, Denmark
- 55 22. Genomic Medicine, Department of Health Science and Technology, Aalborg University,
- 56 Aalborg, Denmark
- 57 23. Statens Serum Institut, Copenhagen, Denmark
- 58 24. Faculty of Medicine, University of Iceland, Reykjavik, Iceland
- 59 25. Children's Hospital Iceland, Landspitali University Hospital, Reykjavik, Iceland
- 60 26. deCODE genetics/Amgen, Inc., Reykjavik, Iceland
- 61 27. Department of Clinical Biochemistry, Landspitali University Hospital, Reykjavik, Iceland
- 62 28. Department of Obstetrics and Gynecology, Landspitali University Hospital, Reykjavik,
- 63 Iceland
- 64 29. Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia
- 65 30. Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of
- 66 Helsinki, Helsinki, Finland
- 67 31. Research Unit of Population Health, Faculty of Medicine, University of Oulu, Finland
- 32. Northern Finland Birth Cohorts, Arctic Biobank, Infrastructure for Population Studies, Faculty
   of Medicine, University of Oulu, Oulu, Finland
- 70 33. Research Unit of Clinical Medicine, Medical Research Center Oulu, University of Oulu, and
- 71 Department of Children and Adolescents, Oulu University Hospital, Oulu, Finland
- 72 34. Centre for Preventive Neurology, Wolfson Institute of Population Health, Queen Mary
- 73 University London, London, EC1M 6BQ, United Kingdom
- 74 35. Department of Biological Psychology, Netherlands Twin Register, Vrije Universiteit,
- 75 Amsterdam, The Netherlands
- 76 36. Amsterdam Reproduction and Development Institute, Amsterdam, The Netherlands
- 77 37. Harvard Reproductive Sciences Center and Reproductive Endocrine Unit, Massachusetts
- 78 General Hospital, Boston, Massachusetts, United States of America
- 79 38. Harvard Medical School, Boston, Massachusetts, United States of America
- 80 39. Medical and Clinical Genetics, University of Helsinki and Helsinki University Hospital,
- 81 Helsinki, Finland
- 82 40. Department of Obstetrics and Gynecology, Tampere University Hospital, Finland

- 41. Center for Child, Adolescent, and Maternal Health Research, Faculty of Medicine and
- 84 Health Technology, Tampere University, Finland
- 42. Blizard Institute, Queen Mary University London, London, E1 2AT, United Kingdom
- 43. Division of Endocrinology, Department of Pediatrics, Boston Children's Hospital, Boston,
- 87 Massachusetts, United States of America
- 44. Broad Institute of Harvard and MIT, Cambridge, Massachusetts, United States of America

# 89 Abstract

90 Genome-wide association studies (GWASs) may help inform treatments for infertility, whose 91 causes remain unknown in many cases. Here we present GWAS meta-analyses across six 92 cohorts for male and female infertility in up to 41,200 cases and 687,005 controls. We identified 21 genetic risk loci for infertility (P≤5E-08), of which 12 have not been reported for any 93 94 reproductive condition. We found positive genetic correlations between endometriosis and all-95 cause female infertility ( $r_g$ =0.585, P=8.98E-14), and between polycystic ovary syndrome and 96 anovulatory infertility ( $r_{a}$ =0.403, P=2.16E-03). The evolutionary persistence of female infertilityrisk alleles in EBAG9 may be explained by recent directional selection. We additionally identified 97 up to 269 genetic loci associated with follicle-stimulating hormone (FSH), luteinising hormone, 98 99 oestradiol, and testosterone through sex-specific GWAS meta-analyses (N=6,095-246,862). 100 While hormone-associated variants near FSHB and ARL14EP colocalised with signals for 101 anovulatory infertility, we found no  $r_{q}$  between female infertility and reproductive hormones 102 (P>0.05). Exome sequencing analyses in the UK Biobank (N=197,340) revealed that women 103 carrying testosterone-lowering rare variants in GPC2 were at higher risk of infertility (OR=2.63, 104 P=1.25E-03). Taken together, our results suggest that while individual genes associated with 105 hormone regulation may be relevant for fertility, there is limited genetic evidence for correlation 106 between reproductive hormones and infertility at the population level. We provide the first 107 comprehensive view of the genetic architecture of infertility across multiple diagnostic criteria in 108 men and women, and characterise its relationship to other health conditions.

# 109 Introduction

110 Infertility, defined as the inability to achieve pregnancy within 12 months of regular unprotected 111 sexual intercourse, affects one in six couples across the globe<sup>1</sup>. A range of demographic, 112 environmental, and genetic factors may drive infertility, including the age-related decline of sperm 113 and oocyte quality and quantity<sup>2,3</sup>, infectious diseases<sup>4–6</sup>, and rare Mendelian disorders such as 114 cystic fibrosis<sup>7,8</sup>. However, the exact cause remains undetermined in up to 28% of couples and 115 40% of women with infertility<sup>9,10</sup>. Given that current treatments such as *in vitro* fertilisation pose physical, emotional, and financial burdens on couples and healthcare systems<sup>11-14</sup>, a richer 116 117 understanding of the biology and pathophysiology of infertility is urgently necessary.

118

119 Heritable women's reproductive health diseases, particularly endometriosis<sup>15</sup> and polycystic ovary 120 syndrome (PCOS)<sup>16</sup>, are thought to be responsible for a considerable proportion of female 121 infertility, with PCOS in particular accounting for up to 80% of cases of anovulatory infertility<sup>17</sup>. It 122 is hypothesised that sex-hormone dysregulation<sup>18,19</sup> and obesity<sup>20</sup>, which often accompany 123 reproductive diseases, may be involved in the aetiology of infertility. Yet little is known about the 124 genetic basis of reproductive hormones and infertility, which are not well-phenotyped in men or 125 women in large studies<sup>21,22</sup>. Moreover, negative selection against infertility naturally limits the frequency of risk alleles in the population<sup>23</sup>. Genome-wide association studies (GWASs) have 126 thus typically queried proxy measures of fertility such as childlessness<sup>24,25</sup>, which may partly arise 127 128 from socio-economic and behavioural factors.

129

130 We aggregated data from a range of sources, including primary care and hospital electronic health 131 records (EHRs) and self-report, across six cohorts with over 1 million participants, to perform the 132 first reported GWAS meta-analyses for male infertility and five categories of female infertility. In 133 addition, we report results from the largest sex-specific GWASs to date for five reproductive 134 hormones. By aggregating this data with complementary rare variant genetic association testing from the UK Biobank, we catalogue the common and rare genetic contributions to infertility and 135 136 reproductive hormone levels, quantify the extent of shared genetic architecture between these 137 traits, and prioritise genes and cell types for further functional investigation of the hormonal and 138 non-hormonal drivers of infertility.

# 139 **Results**

# 140 Genome-wide meta-analyses identify novel genetic loci for female

141 and male infertility

We identified female infertility of all causes (F-ALL), anatomical causes (F-ANAT), anovulation (F-ANOV), unknown causes, i.e., idiopathic infertility as defined by exclusion of known causes of infertility (anatomical or anovulatory causes, PCOS, endometriosis, or uterine leiomyomas) (F-EXCL), or idiopathic infertility defined by inclusion of diagnostic codes for idiopathic infertility (F-

146 INCL), as well as male infertility of all causes (M-ALL) in six cohorts, primarily of European

147 ancestry (Figure 1 and Supp. Tables 1 and 2). The case-control ratio of all-cause female infertility 148 ranged from 0.9% in the deCODE Genetics dataset<sup>26</sup> to 11.7% in FinnGen<sup>27</sup>, whereas the case-149 control ratio of male infertility was between 0.3% (UKBB) and 8.2% (Danish Biobank) (Figure 1 150 and Supp. Table 2). Anatomical female infertility was the least common cause of infertility in three 151 of six cohorts (prevalence in UKBB=0.01%, EstBB=2.0%, FinnGen=0.8%). Due to varying sample 152 ascertainment, the case-control ratio does not necessarily reflect the population prevalence of 153 infertility.

154



155

156 Figure 1. Overview of study cohorts and analyses presented for infertility genetic association studies. (A) Case numbers in each cohort contributing cases to genome-wide association study (GWAS) 157 158 meta-analyses (MA) for female (left) and male (right) infertility. The prevalence of all-cause infertility in each 159 cohort (%) is noted on the barplots. EUR=European ancestry, SAS=South Asian ancestry. EstBB=Estonian 160 Biobank, Danish=Danish Blood Donor Study/Copenhagen Hospital Biobank, UKBB=UK Biobank, 161 G&H=Genes and Health cohort. Total case and control counts for each type of genetic analysis: all ancestry 162 GWAS meta-analysis (dark rectangles), EUR-only GWAS meta-analysis (light rectangles), and UK Biobank 163 whole exome sequencing (WES) analyses (black outlined rectangles) are displayed. Male infertility in

deCode, with <100 cases, was excluded from GWAS MA. Note the different Y-axis scales in each subplot.</li>
 (B) Downstream analyses performed for each type of genetic analysis: lead variants were identified via
 distance-based pruning for all-ancestry and EUR-only GWAS meta-analyses; colocalisation, genetic
 correlation, and selection analyses were only performed for EUR meta-analyses due to the need for
 ancestry-matched linkage disequilibrium (LD) information; rare variant and gene burden tests were
 performed with WES data for the UK Biobank EUR-ancestry subset.

#### 170 Novel genetic loci for infertility

We performed GWAS meta-analyses, testing up to 28.4 million genetic variants for associations with each of the above categories of infertility, in up to 41,200 cases/687,005 controls in women, and 7,098 cases/428,364 controls in men (Figure 1 and Supp. Table 2). We identified 19 unique genome-wide significant (GWS, *P*<5E-8) loci associated with at least one category of female infertility and two loci for male infertility (minor allele frequency (MAF) range 0.24%-46%, lead variants reported in at least two cohorts) (Figure 2, Table 1, and Supp. Figure 1). There was no evidence for heterogeneity in lead variant effects across cohorts (Supp. Text).

178

179 Among the variants associated with multiple subtypes of female infertility is rs1964514, an intronic 180 variant in PKHD1L1 (OR (95% CI) for F-ALL=1.13 (1.09-1.16), F-EXCL=1.13 (1.09-1.17), F-181 INCL=1.18 (1.11-1.25)). This variant is 76 kb upstream of EBAG9, an oestrogen-responsive gene 182 previously reported to have a recessive association with female infertility<sup>28</sup> and thought to 183 suppress maternal immune response during pregnancy<sup>29,30</sup>. We also identified an intronic variant 184 in WNT4, rs61768001, associated with three categories of female infertility (F-ALL=0.909 (0.891-0.927), F-EXCL=0.923 (0.902-0.946), F-INCL=0.870 (0.839-0.903)). WNT4 is highly pleiotropic 185 for female reproductive traits, as it is reported to associate with destational length<sup>31</sup>, uterine 186 fibroids<sup>32,33</sup>, endometriosis<sup>34,35</sup>, female genital prolapse<sup>27</sup>, and bilateral oophorectomy<sup>27</sup>. Such 187 188 pleiotropy is expected, as WNT4 is a key regulator of female reproductive organ development in 189 embryogenesis<sup>36–38</sup>.

190

191 The nearest gene to the idiopathic infertility-associated variant rs111597692 (F-EXCL OR=1.16 192 (1.10-1.22)) is *TRHR*, which encodes the thyrotropin-releasing hormone receptor. Mice with 193 *TRHR* knockouts display a phenotype similar to primary ovarian insufficiency<sup>39,40</sup>. The F-ANOV 194 associated variant rs72827480 (OR=0.905 (0.873-0.938)) colocalises with a testis-eQTL for 195 *INHBB* in the GTEx Project<sup>41</sup> (posterior probability (PP) of shared causal variant=91.6%) (Supp. 196 Table 4). *INHBB* encodes the beta subunit of inhibin B, which regulates hypothalamic, pituitary, 197 and gonadal hormone secretion<sup>42</sup>, and ovarian follicle and oocyte development<sup>43</sup>.

198

Finally, an intronic variant in *ENO4*, which is expressed in the testis and may play a role in sperm motility<sup>44</sup>, is associated with male infertility (rs139862664, OR=0.388 (0.277-0.543)). Male mice with *ENO4* knockouts display infertility, abnormal sperm morphology and physiology, and decreased testis weight, among other altered male reproductive tract phenotypes<sup>45</sup>.



204 Figure 2. Miami and Manhattan plots for selected infertility meta-analyses. (A) Genetic variants 205 associated with female infertility of all causes (F-ALL) (top) and idiopathic infertility (unknown causes) 206 defined by exclusion of known causes such as anatomical or anovulatory causes, PCOS, endometriosis, 207 or uterine leiomyomas (bottom). (B) Genetic variants associated with male infertility of all causes (M-ALL). Each point depicts a single SNP, with genome-wide significant (GWS) SNPs (P<5E-08, dashed line) 208 209 coloured in pink for common variants with minor allele frequency (MAF)>=1% and green for those with 210 MAF<1%. SNPs are annotated with the mapped gene. \* indicates that lead variant is reported in only one 211 cohort.

Table 1. Lead variants associated with infertility in GWAS meta-analyses. A1 is the effect allele. \*lead variant is reported in only one cohort.

	chr:pos:A1:A2 (hg38)	Mapped gene		All ancestries		EUR only					
RSID			Average MAF	OR (95% CI)	P-value	Average MAF	OR (95% CI)	P-value			
Female infertility of all causes (F-ALL)											
rs61768001	chr1:22139327:T:C	WNT4	0.166	0.909 (0.891-0.927)	2.25E-21	0.163	0.911 (0.893-0.93)	1.24E-19			
rs10200851	chr2:11581956:T:C	GREB1	0.458	0.951 (0.937-0.965)	2.90E-11	0.456	0.951 (0.936-0.965)	5.84E-11			
rs6938404	chr6:151222906:T:C	AKAP12	0.453	0.958 (0.943-0.973)	3.88E-08	0.453	0.958 (0.943-0.973)	3.88E-08			
rs17803970	chr6:152232583:A:T	SYNE1	0.0836	1.09 (1.06-1.12)	1.91E-10	0.0836	1.10 (1.07-1.13)	7.50E-11			
rs1964514	chr8:109463457:C:G	EBAG9	0.0595	1.13 (1.09-1.16)	3.01E-14	0.0597	1.13 (1.09-1.16)	6.68E-14			
Anatomical female infertility (F-ANAT)											
rs340879	chr1:213983171:T:C	PROX1	0.418	0.906 (0.874-0.939)	4.95E-08	0.418	0.902 (0.869-0.936)	5.06E-08			
Anovulatory female infertility (F-ANOV)											
rs72665317	chr1:22040580:T:G	CDC42	0.190	0.875 (0.839-0.913)	7.76E-10	0.18	0.886 (0.847-0.927)	1.45E-07			
rs72827480	chr2:120388925:T:C	INHBB	0.401	0.905 (0.873-0.938)	4.20E-08	0.401	0.905 (0.873-0.938)	4.20E-08			
rs1852684	chr2:145068818:T:G	ZEB2	0.367	1.12 (1.08-1.16)	9.25E-10	0.35	1.12 (1.08-1.17)	3.44E-10			
rs552953683	chr8:102898586:T:C	AZIN1	0.0024	0.341 (0.234-0.498)	2.54E-08	0.0024	0.341 (0.234-0.498)	2.54E-08			
rs9696009	chr9:123856954:A:G	DENND1A	0.0777	1.21 (1.14-1.29)	6.87E-10	0.0695	1.24 (1.16-1.32)	2.40E-10			
rs9902027	chr17:7537667:T:C	TNFSF12	0.255	0.895 (0.86-0.931)	4.06E-08	0.255	0.895 (0.86-0.931)	4.06E-08			
rs143459581	chr22:28068862:T:C	PITPNB	0.0419	1.30 (1.19-1.43)	1.21E-08	0.0419	1.30 (1.19-1.43)	1.21E-08			
rs17879961	chr22:28725099:A:G	CHEK2	0.0389	0.739 (0.673-0.811)	1.55E-10	0.0389	0.739 (0.673-0.811)	1.55E-10			
		ldi	opathic fem	ale infertility, exclusion d	lefinition (F-EX	(CL)					
rs61768001	chr1:22139327:T:C	WNT4	0.165	0.923 (0.902-0.946)	7.49E-11	0.162	0.928 (0.906-0.951)	2.48E-09			
rs111597692	chr8:109039973:T:C	TRHR	0.0323	1.16 (1.10-1.22)	1.51E-08	0.0323	1.16 (1.1-1.22)	1.51E-08			
rs17378154	chr8:109568721:A:G	EBAG9	0.059	1.13 (1.09-1.17)	1.64E-10	0.0593	1.13 (1.09-1.17)	3.36E-10			
		ld	iopathic fen	nale infertility, inclusion d	lefinition (F-IN	CL)					
rs61768001	chr1:22139327:T:C	WNT4	0.170	0.87 (0.839-0.903)	6.87E-14	0.165	0.872 (0.840-0.905)	8.96E-13			
rs11692588	chr2:11544358:A:G	GREB1	0.358	0.919 (0.892-0.947)	2.98E-08	0.358	0.919 (0.892-0.947)	2.98E-08			
rs190290095	chr4:39786858:A:G	UBE2K	0.0022	0.227 (0.137-0.375)	7.60E-09	0.0022	0.227 (0.137-0.375)	7.60E-09			
rs851982	chr6:151703850:T:C	ESR1	0.428	0.921 (0.895-0.947)	7.60E-09	0.437	0.922 (0.896-0.949)	2.86E-08			
rs17378154	chr8:109568721:A:G	EBAG9	0.0565	1.18 (1.11-1.25)	2.47E-08	0.0569	1.18 (1.11-1.25)	4.97E-08			
rs74156208	chr10:61509370:A:G	TMEM26	0.184	1.10 (1.06-1.14)	4.96E-08	0.187	1.10 (1.07-1.15)	5.44E-08			
Male infertility of all causes (M-ALL)											
rs1228269928*	chr2:132923776:A:T	NCKAP5	0.0006	0.0995 (0.0441-0.224)	2.72E-08	0.0006	0.0995 (0.0441-0.224)	2.72E-08			
rs150639836	chr10:53879806:T:C	PCDH15	0.0109	0.505 (0.402-0.636)	5.72E-09	0.0109	0.505 (0.402-0.636)	5.72E-09			
rs139862664	chr10:116879589:C:G	ENO4	0.0072	0.388 (0.277-0.543)	3.29E-08	0.0072	0.388 (0.277-0.543)	3.29E-08			

#### 215 Genetic relationships between infertility and female reproductive conditions

Genome-wide, we observed positive genetic correlation between endometriosis and F-ALL ( $r_g$ (SE)=0.585 (0.0785), *P*=8.98E-14) and F-INCL ( $r_g$ =0.710 (0.115), *P*=5.94E-10). We also observed positive correlation between F-ANOV and PCOS, the most common cause of anovulatory infertility ( $r_g$ =0.403 (0.131), *P*=2.20E-3), and negative correlation between F-ANOV and spontaneous dizygotic twinning, a heritable metric of female fecundity that captures the propensity for multiple ovulation<sup>46</sup> ( $r_g$ =-0.740 (0.182), *P*=4.93E-05).

222

Two loci associated with both endometriosis and female infertility - *WNT4* and *ESR1* - may share the same putative causal variant (PP>93.6%, Supp. Table 5). Variants in both these genes have previously been associated with endometriosis-related infertility<sup>47–50</sup>. While *GREB1* and *SYNE1* also contain overlapping signals for infertility and endometriosis, there is strong evidence against shared causal variants (PP>75%, Supp. Table 5). Finally, three of eight loci for anovulatory infertility - *INHBB*, *PITPNB*, and *CHEK2* - may share a causal variant with PCOS (PP>89.2%, Supp. Table 5).



232 Figure 3. Genetic correlations between female infertility and other phenotypes. SNP-based genetic 233 correlations  $(r_g)$  between significantly heritable phenotypes (Z>4) were estimated using LD-score 234 regression, performed using the LDSC software<sup>51</sup> on a subset of 1 million HapMap3 SNPs<sup>52</sup>. Points are 235 coloured by  $r_{\rm q}$  estimate, scaled by significance (-log10(P)), and labelled with the associated  $r_{\rm q}$  estimate if 236 nominally significant without correction for multiple testing (P<0.05). (A) Genetic correlations among the 237 three significantly heritable definitions of female infertility (all cause=F-ALL, anovulatory=F-ANOV, and 238 idiopathic infertility defined by inclusion=F-INCL). (B) Genetic correlations between female infertility traits 239 and reproductive hormones: testosterone, follicle stimulating hormone (FSH), and anti-Mullerian hormone 240 (AMH, publicly available summary statistics) in female-specific analyses, and thyroid stimulating hormone 241 (TSH, publicly available summary statistics) from sex-combined analysis. (C) Genetic correlations between 242 female infertility traits and female reproductive conditions, with summary statistics generated from the 243 largest available European-ancestry studies for each trait (see Methods). PCOS=polycystic ovary 244 syndrome. (D) Genetic correlations between female infertility traits and selected heritable phenotypes (Z>4) 245 in the UK Biobank, as generated by the Neale lab<sup>53</sup>. Correlations with all heritable phenotypes can be found 246 in Supp. Table 12.

# Selection pressure may explain the persistence of some infertility-associated variants in the population

249 The genome-wide SNP heritability estimates (on the liability scale, accounting for disease 250 prevalence<sup>54</sup>) for all categories of infertility are <10% (lowest for M-ALL at 1.12% (SE=0.93) and 251 highest for F-ANOV at 9.54% (2.16)) (Supp. Table 6). This is lower than heritability estimates of 252 two-thirds of all heritable binary phenotypes in the UK Biobank with population prevalence similar 253 to that of infertility (64 phenotypes with Z>4 and prevalence <5%)<sup>53</sup>. We hypothesised that infertility risk-increasing alleles are subject to negative selection<sup>55</sup>, so we tested whether there 254 255 was evidence for: (i) variants associated with infertility in loci under historical or recent directional 256 selection<sup>56–58</sup>, or (ii) recent directional selection (over the last 2,000 to 3,000 years) measured by 257 singleton density scores (SDSs)<sup>56</sup> and balancing selection measured by standardised BetaScan2 scores (StdB2)<sup>59</sup> at infertility loci. 258

259

260 While we found no genome-wide signature of directional selection against infertility (Supp. Text), we observed extreme SDSs (in the highest 99.75th percentile (%ile) of SNPs within 10kb of a 261 262 GWAS Catalog variant) at the EBAG9 locus associated with female infertility, indicating recent 263 positive selection (Figure 4 and Supp. Table 7). EBAG9 is associated with infectious response 264 phenotypes, suggesting that the locus may be under selection for its effects on the immune 265 system. We additionally observed signatures of balancing selection, which maintains multiple 266 alleles in the population through mechanisms such as heterozygote advantage or time-varying fitness<sup>60,61</sup>, at the female infertility loci GREB1 (StdB2 in the 98.6<sup>th</sup>-99.4<sup>th</sup> %ile of SNPs within 10kb 267 268 of a GWAS Catalog variant) and INHBB (98.5<sup>th</sup> %ile), and the male infertility locus PCDH15 (98.7<sup>th</sup> 269 %ile); however, variants at these loci with high probability of association with infertility did not 270 have high balancing selection scores (Supp. Figure 2 and Supp. Table 7).



271

272 Figure 4. Directional selection scores at infertility-associated EBAG9 locus. Recent directional 273 selection, as measured by trait-aligned Singleton Density Scores (tSDSs) at the EBAG9 locus. The window 274 of +/- 10 kb around the lead variant associated with female infertility of all causes (F-ALL) is displayed, 275 along with the location of nearest gene transcription start sites (TSSs). The tSDSs are aligned to the 276 infertility-risk increasing allele, wherein a positive tSDS indicates positive selection for infertility-risk 277 increasing allele at the locus. Dashed lines indicate 2.5th percentile (%ile) and 97.5th %ile of SDSs, and 278 variants below or above this threshold respectively are coloured in pink. Left: Locus plots depicting genomic 279 position on the x-axis and tSDS on the y-axis. The lead variant rs1964514 (open circle) is not present in 280 the tSDS dataset and thus assigned a score of 0. Right: Scatter plots depicting relationship between -log10 281 of the GWAS p-value for the variant association with F-ALL on the x-axis and tSDS on the y-axis.

# 282 Genetic determinants of reproductive hormone levels

#### 283 Identification of novel reproductive hormone loci

As hormone dysregulation is central to many infertility diagnoses<sup>18,19</sup>, we conducted sex-specific 284 GWAS meta-analyses of five reproductive hormones - follicle-stimulating hormone (FSH) 285 286 (N<sub>female</sub>=57,890, N<sub>male</sub>=6,095), luteinising hormone (LH) (N<sub>female</sub>=47,986, N<sub>male</sub>=6,769), oestradiol 287 progesterone (N<sub>female</sub>=18,368), and total testosterone (N<sub>female</sub>=97,887, N<sub>male</sub>=39,165), 288 (N<sub>female</sub>=246,862, N<sub>male</sub>=243,951) - collected at assessment centre visits or identified through 289 EHRs, in six cohorts and publicly available summary statistics (Supp. Table 9). We identified GWS 290 loci associated with FSH (9 novel/2 previously known in females (F) and 0/1 in males (M)), LH 291 (4/2 in F and 1/0 in M), oestradiol (1/1 in F and 2/4 in M), and testosterone (35/118 in F and 55/206 292 in M), but found no genetic variants associated with progesterone (Figure 5, Supp. Figure 3, and 293 Supp. Figure 4). Several of the reported signals we replicated are near genes encoding the 294 hormone-specific subunits themselves, such as FSHB for FSH and LHB for LH, or enzymes for 295 steroid hormone metabolism, such as CYP3A7 for oestradiol and HSD17B13 for testosterone 296 (Supp. Text).



297

298 Figure 5. Number of novel and reported reproductive hormone associations. Each panel displays a 299 different hormone (FSH=follicle-stimulating hormone, LH=luteinising hormone). Lead variants in each 300 analysis stratum (F=female-specific, M=male-specific, all-anc=all ancestry meta-analysis, EUR=European-301 only meta-analysis) are classified as: (1) novel (no hormone associations) if they are not in LD ( $r^2 < 0.1$ ) with, 302 and conditionally independent of (conditional *P*-value *P*<sub>cond</sub><0.05), any variants within a 1Mb window of the 303 lead variant that are associated with 28 reproductive hormones in the GWAS Catalog<sup>62</sup>, plotted in pink, (2) 304 novel for this hormone if they are not in LD ( $r^2 < 0.1$ ) with, and conditionally independent of ( $P_{cond} < 0.05$ ), the 305 respective hormone-associated variants within a 1Mb window of the lead variant, plotted in green, and (3) 306 reported otherwise, plotted in grey. Note the different Y-axis scales in each subplot. assocns.=associations. We further classified lead variants as entirely novel hormone associations by defining a protocol based on linkage disequilibrium (LD) and conditional independence from published SNPs associated with any of 28 reproductive hormones in the GWAS Catalog<sup>62</sup> (see Methods for detailed classification protocol).

311

312 We found 39 novel variants for testosterone in men, including those near SPOCK1 (rs1073917: 313  $\beta$  (SE)=-0.0160 (0.0029), P=4.69E-08), which is a target for the androgen receptor<sup>63</sup>, NR4A3 (rs10988865:  $\beta$ =-0.0161 (0.0029), P=4.33E-08), which coordinates the cellular response to 314 315 stimuli<sup>64,65</sup> corticotropin-hormone and thyrotropin-hormone releasing and regulates adipogenesis<sup>66</sup>, and obesity-associated genes ANKS1B (rs144998814:  $\beta$ =0.133 (0.0162), 316 317 *P*=2.34E-16) and *ANO10* (rs6809522: β=0.016 (0.0029), *P*=3.00E-08)<sup>67</sup> (Supp. Table 10). The 28 318 novel reproductive hormone variants associated with testosterone in women include those near 319 LAMTOR4 (rs17250196: β=-0.131 (0.0067), P=4.02E-86), associated with hyperthyroidism<sup>39</sup> and age at menarche and menopause<sup>68</sup>, obesity-associated CCDC146 (rs138240474:  $\beta$ =-0.116 320 321 (0.0207), P=2.03E-08)<sup>67</sup>, which is also expressed in the fallopian tubes and endometrium<sup>69,70</sup>, and 322 SLC8A1 (rs12611602: β=0.0163 (0.003), P=3.79E-08), which causes increased pancreatic beta 323 cell proliferation and insulin secretion in knockout mouse models<sup>71</sup>. Finally, we report lead SNPs 324 independent of previously published hormone variants in the HELQ locus for FSH-F (rs4235062: 325 β=-0.046 (0.0065), P=1.50E-12), TMEM150B locus for FSH-F (rs28875253: β=-0.0599 (0.0061), 326 P=9.90E-23) and LH-F (rs11668309: β=0.0519 (0.0071), P=3.91E-13), and in the SOX15-SAT2 327 locus for oestradiol-F (rs3933469: β=0.0363 (0.0051), P=1.02E-12) (Supp. Table 10).

328

329 Our results were robust to the inclusion of summary statistics from publicly available datasets, 330 and there was no evidence for heterogeneity in variant effects across cohorts (Supp. Text).

#### 331 Sex-specific genetic architecture of testosterone

332 Only 9.80% (of 153 total) lead variants for testosterone in females and 5.75% (of 261 total) lead 333 variants for testosterone in males reach GWS in both sexes; and 45.9% of variants have opposing 334 directions of effect in men and women (Supp. Figure 6). Indeed, we found no significant genetic correlation between testosterone in men and women ( $r_g$  (SE)=0.0361 (0.0428), P=0.399). The 335 336 heritability of testosterone in women is enriched in the adrenal gland (P=1.03E-03) and 337 hepatocytes (P=9.36E-04); but only the latter is enriched for the heritability of testosterone in men 338 (P=3.61E-04), as is the liver more broadly (P=1.16E-06) (Supp. Figure 10, stratified LD-score 339 regression performed across 205 tissues and cell-types from the Genotype Tissue Expression (GTEx) Project database<sup>41</sup> and the Franke lab single-cell database<sup>72</sup>). Finally, although 340 341 testosterone regulates several traits hypothesised to be under sexual selection and may be under 342 selection itself<sup>73</sup>, we do not find significant genome-wide directional selection for testosterone in 343 men or women (mean genome-wide trait-SDS is not significantly different from 0, both P>0.05) 344 (Supp. Text).

# 345 Genetic relationships between female infertility, reproductive 346 hormones, and obesity

We observed no genome-wide genetic correlations between any category of female infertility and: (i) any reproductive hormone in this study, or (ii) thyroid stimulating hormone (TSH), or (iii) anti-Mullerian hormone (AMH), the latter two based on publicly available summary statistics<sup>74,75</sup> (all P>0.05, Figure 3B). Mendelian randomisation (MR) analyses indicated a genetically causal protective effect of FSH on risk of F-ALL (OR (95% CI)=0.776 (0.678-0.888), P=2.15E-04) and F-EXCL (0.716 (0.604-0.850), P=1.26E-04) (Supp. Table 11).

353

We found evidence for shared variants between hormones and infertility at the *FSHB* locus associated with FSH, LH, and testosterone (PP>84.8% for colocalisation with F-ANOV), and the *ARL14EP* locus associated with LH (PP=89.3% for colocalisation with F-ANOV) (Supp. Table 12). There was no evidence for colocalisation at any of the >300 other GWS loci associated with infertility or reproductive hormones in our study (Supp. Table 12). Our results suggest that while these traits are not significantly correlated at a genome-wide level, a small number of genes may drive infertility linked to hormone dysregulation.

361

362 Across 703 heritable phenotypes in the UK Biobank, we found 15 traits to be genetically correlated 363 with female infertility, which we broadly group into: female reproductive conditions (such as having 364 had a hysterectomy,  $r_g$  (SE)=0.481 (0.0963)), general illness (such as number of operations, 365  $r_q=0.266$  (0.0588)), and cognitive test results (overall prospective memory test  $r_q=0.345$  (0.0736), 366 overall fluid intelligence  $r_0$ =-0.276 (0.0502)) (Figure 3D and Supp. Table 13). 24 obesity-related 367 traits, including body mass index (BMI), waist-to-hip ratio (WHR), and body fat percentage, are 368 correlated with testosterone and FSH, but are not genetically correlated with any category of 369 female infertility (all P>0.05, Figure 3D, Supp. Figure 7, and Supp. Table 13). However, MR 370 analyses using genetic instruments for BMI, WHR, and WHR adjusted for BMI (WHRadjBMI)<sup>67</sup> 371 indicated evidence for bi-directional causal relationships between infertility and abdominal obesity 372 independent of overall obesity. While genetically predicted WHRadiBMI is a risk factor for F-ALL 373 (OR (95% CI)=1.10 (1.05-1.16), P=1.71E-04) and F-ANOV (1.29 (1.16-1.45), P=4.66E-06), the 374 latter is itself causal for increased WHRadjBMI (β (SE)=0.0547 (0.0133), P=3.74E-05) (Supp. 375 Table 11).

376

Variants associated with all-cause female infertility are in genes enriched for expression in ovarian stromal cells (partitioned heritability P=2.52E-03). We did not find significant enrichment of infertility heritability in any of the 205 tissues and cell-types from the GTEx project database<sup>41</sup> and the Franke lab single-cell database<sup>72</sup>.

# Rare variant contribution to reproductive-hormone and infertility genetics

We analysed the 450k UK Biobank exome sequencing dataset to characterise the association between rare coding variation (MAF<1%) and binary traits with >100 cases (F-ALL (3,746 cases,

260.413 controls), F-EXCL (3.012 cases, 261.147 controls), and M-ALL (650 cases, 222.393 385 386 controls)), and quantitative traits with >10,000 participants (FSH-F (N=20,800), LH-F (N=16,391), 387 oestradiol-F (N=54,609), and testosterone ( $N_{female}$ =197,038,  $N_{male}$ =197,340) (Figure 1)). Geneburden analyses implicate the *PLEKHG4* gene, which is highly expressed in the testis and ovary, 388 389 for F-EXCL (burden test OR (95% CI)=1.04 (1.02-1.06) when aggregated across all variant annotations with MAF<1%, Cauchy P=1.37E-08) (Supp. Table 14). Rare variants in PLEKHG4 390 391 cause cerebellar ataxia<sup>76</sup>, which is a feature of some syndromes that also cause steroid hormone 392 deficiency and hypogonadism<sup>77,78</sup>.

393 Novel genes for testosterone implicated by gene burden analyses

394 Gene-based analyses identify 27 genes associated with testosterone-F and 24 genes for 395 testosterone-M (P<5E-06), of which eleven have not previously been implicated in GWASs (Supp. 396 Text). We report the first known association of HSD11B1 with testosterone-F (burden test 397 P=1.93E-06 when aggregated across missense variants with MAF<0.01%); pathogenic variants 398 in this gene are reported to cause hyperandrogenism due to cortisone reductase deficiency<sup>79,80</sup> 399 (Supp. Figure 11 and Supp. Table 14). We also report the association of testosterone-M with 400 HSD17B2 (burden test P=1.33E-11 when aggregated across pLoF variants with MAF<0.1%), 401 which encodes the enzyme hydroxysteroid  $17\beta$ -dehydrogenase 2 that catalyses the oxidation of 402 oestradiol, testosterone, and dihydrotestosterone to less active forms and thus regulates the 403 biological potency of steroid hormones<sup>81,82</sup> (Supp. Figure 11 and Supp. Table 14).

#### 404 Increased risk of infertility in individuals carrying rare testosterone-405 associated variants

406 Two genes associated with testosterone in female UK Biobank participants are also associated 407 with infertility risk (P<1.00E-03, Bonferroni adjustment for 50 unique genes): *TRIM4* (F-ALL, 408 burden test OR=1.03 (1.01-1.05), P=4.05E-04 across all variants with MAF<0.1%) and *CYP3A43* 409 (F-EXCL, burden test OR=1.02 (1.01-1.03), P=4.84E-04 across all variants with MAF<1%). The 410 latter encodes the steroid hormone metabolic enzyme testosterone 6-beta-hydroxylase; but 411 neither gene has previously been implicated in infertility.

412

Finally, we identified 29 unique genes carrying rare variants (MAF<1%) associated with testosterone in male or female participants in the UK Biobank. Eighteen of the 29 genes also contain common testosterone-associated variants from GWASs (MAF>1%), but the rare variant has a larger absolute effect size in the majority (83%) of these (Figure 6A, Supp. Table 15, and Supp. Text).



418 419

420 Figure 6. Rare variants associated with testosterone and infertility in UK Biobank whole exome 421 sequencing (WES) analyses. (A) Effect size versus allele frequency of genetic variants associated with 422 total testosterone. Variants discovered at genome-wide significance (P<5E-08) in GWAS meta-analyses 423 (coloured in grey) and exome-wide significance in the UK Biobank WES analyses (coloured in black) are 424 plotted, sized by the absolute value of their effect size. Effect sizes are aligned to the minor allele, plotted 425 against MAF on the log x-axis. (B) Effects of testosterone-associated rare variants on infertility in females 426 (left) and males (right). Per gene, the variant with lowest P-value of all variants that reach exome-wide 427 significance (P<1E-07) in UK Biobank WES analyses for testosterone is displayed, for all variants with 428 nominally significant effects on infertility. Effect sizes (β and 95% confidence intervals (CIs) for the variant 429 effect on testosterone are to the left of each plot, and effect sizes (odds ratios (ORs) and 95% CIs) for the 430 variant effect on infertility are to the right of each plot. Variants that reach nominal significance (P<0.05) are 431 coloured in solid shapes.

432

433 The eleven novel testosterone associations include a female testosterone-lowering missense 434 variant in STAG3 (chr7:100204708:C:T,  $\beta$ =-0.284, P=2.31E-08); STAG3 is also associated with 435 primary ovarian insufficiency in women<sup>83,84</sup>, and induces female infertility through the absence of oocytes in knockout mouse models<sup>39</sup>. While we did not find significant association between the 436 437 STAG3 variant and female infertility in the UK Biobank (P>0.05), we observed increased risk of 438 idiopathic infertility in women carrying a novel testosterone-lowering variant in GPC2 (chr7:100171569:G:A, F-EXCL OR=2.63 (1.40-4.92), P=1.25E-03) (Figure 6B). GPC2 is highly 439 440 expressed in the testis, and GPC2-knockout mouse models display reduced adrenal gland size<sup>39</sup>.

The gene has not previously been reported to be associated with testosterone or infertility. Taken
together, our results indicate a potential role for infertility driven by rare hormone-disrupting
variants.

# 444 Discussion

445 Our large-scale genetic investigation of infertility and related reproductive phenotypes in over 1 446 million individuals identified 19 genetic loci associated with female infertility, two with male 447 infertility, and novel variants for the reproductive hormones FSH (3 novel variants), LH (1), 448 oestradiol (1), and total testosterone (28) in women and for total testosterone in men (39). Through 449 rare-variant and gene-based analyses in the UK Biobank, we additionally identified PLEKHG4 450 associated with female infertility and 50 genes for testosterone, including the first reported 451 hormone-associated variants in some members of the hydroxysteroid dehydrogenase enzyme 452 family. We found evidence at non-hormonal, pleiotropic, infertility loci for recent directional 453 selection (EBAG9) and balancing selection (GREB1, INHBB, PCDH15). Although there was 454 evidence for distinct genetic architectures of infertility and reproductive hormones, we showed 455 that individual genes containing rare protein-coding variants associated with testosterone (GPC2, 456 CYP3A43, TRIM4) were also associated with higher risk of infertility in the UK Biobank.

457

458 Previous efforts to catalogue the genome-wide architecture of infertility have relied on proxy measures such as childlessness and number of children ever born<sup>24,25</sup>, which may be confounded 459 460 by behavioural, socio-economic, and lifestyle factors. While we did find modest genetic correlation 461 between female infertility and age at first sexual intercourse (-18.8%), indicating that the latter captures some shared biology with fertility, our meta-analyses did not replicate the associations 462 of infertility proxy variables with putative behavioural loci for risk-taking<sup>85,86</sup> or educational 463 464 attainment<sup>85,87–89</sup>. Instead, we nominate genes with putative roles in both male and female 465 gonads, such as *TRHR* for ovarian insufficiency<sup>39,40</sup> and *ENO4* for sperm motility<sup>44</sup>.

466

467 The strong genetic correlation of 71% between idiopathic infertility and endometriosis may 468 indicate that some proportion of idiopathic cases are due to under-diagnosis of endometriosis. whose early treatment may prevent future infertility<sup>15,90</sup>. Our subtype-specific analyses highlight 469 470 the value in dissecting heterogeneous causes of infertility. For example, PCOS is a heritable 471 cause of up to 80% of anovulatory infertility cases that may be treated through induced 472 ovulation<sup>17,91,92</sup>. However, as only three of eight loci for anovulatory infertility colocalise with known 473 PCOS signals and the genetic correlation between these traits is only 40%, other hypothalamic-474 pituitary-ovarian disorders, endocrinopathies (hypothyroidism, hyperprolactinaemia, etc.) and 475 ovarian insufficiency may also contribute significantly to the genetic aetiology of anovulatory 476 infertility and require treatments different from those for PCOS-associated infertility<sup>93</sup>. Weight loss 477 for overweight patients is often recommended as beneficial for fertility<sup>94,95</sup>, but we did not find 478 substantial genetic correlation between obesity and infertility. Our findings add genetic support to 479 evidence from randomised controlled trials demonstrating no fertility benefits from short-term 480 weight loss in overweight and obese women<sup>96</sup>. Instead, we observed bi-directional causal 481 relationships between abdominal obesity and anovulatory infertility, suggesting physiological 482 feedback mechanisms whose complex interplay requires deeper study. Taken together, these

results suggest a critical need for a richer understanding of the genetic and non-geneticcontributions to infertility.

485

486 The testes and ovaries were not significantly enriched for the heritability of infertility or 487 testosterone, despite being reproductive organs that are major sites for testosterone 488 production<sup>97,98</sup>. However, neither organ is disaggregated into tissues or cell types in the GTEx 489 database, so gene expression profiles may not capture cell-type specific effects. Indeed, we found 490 enrichment of testosterone heritability in the androgen-secreting thecal cells and androgenresponsive granulosa cells of the ovary<sup>99-101</sup>, and female infertility in ovarian stromal cells. 491 492 Although there are several causal roles hypothesised for stromal dysfunction in infertility, such as 493 impaired folliculogenesis<sup>102</sup>, restricted blood flow<sup>103</sup>, and ovarian scarring<sup>104</sup>, more work is needed 494 to robustly replicate these findings. In general, more functional studies of gonadal cell types, in 495 both men and women, are needed to enable a mechanistic understanding of the genetic variation 496 associated with reproductive hormones and infertility.

497

498 We employed a broad search strategy to maximise sample sizes for cases of infertility and 499 reproductive hormone levels in our meta-analyses. Diagnostic criteria for infertility vary by country 500 and have changed over time<sup>1</sup>, which may explain the wide spread in the prevalence of infertility 501 across cohorts. Reproductive hormone values in this study were assayed using different 502 methodologies, in primary care or hospital EHRs, and at different ages and stages of the 503 menstrual cycle in women. A majority of samples in our study were derived from the UK Biobank 504 and measured during and post-menopause (ages 40-69), whereas infertility occurs pre-505 menopause, so we urge caution in interpreting the lack of correlation between these traits. 506 Although we were able to adjust for covariates such as age, which can account for some of the 507 effect of menopause on hormone levels, we did not have the data granularity to account for 508 hormonal fluctuations during the menstrual cycle and pregnancy. In the future, longitudinal 509 GWASs that can incorporate mean and variance of hormone levels over the menstrual cycle, or 510 phenotypes that calculate ratios between various hormones over time, will likely reveal 511 fundamental biology that is missed by the broad-stroke assessments in this study.

512

513 Our results indicate that balancing selection and recent positive selection at pleiotropic loci may 514 explain the persistence of genetic factors for infertility. For example, the EBAG9 locus associated 515 with female infertility is under directional selection, perhaps because EBAG9, which is highly expressed in CD34-/CD41+/CD42+ megakaryocytes<sup>69,70</sup>, plays a role in T-cell mediated 516 517 cytotoxicity as part of the adaptive immune memory response to infection<sup>105</sup>. However, a 518 complementary role for *EBAG9* may be in the placenta during early pregnancy, where reduction 519 of EBAG9 levels is associated with inappropriate activation of the maternal immune system and 520 results in foetal rejection<sup>106</sup>.

521

522 In conclusion, in this comprehensive large-scale investigation of the genetic determinants of 523 infertility and reproductive hormones across men and women, we identified several genes 524 associated with infertility and analysed their effects on reproductive disease and selection 525 pressures. We did not find evidence that reproductive hormone dysregulation and obesity are 526 strongly correlated with infertility at the population level, but instead nominate individual hormone527 associated genes with effects on fertility. Other genetic and non-genetic avenues must be 528 explored to treat complex and heterogeneous fertility disorders that impact the physical, 529 emotional, and financial well-being of millions of individuals across the globe.

# 530 Methods

# 531 Study populations and phenotype identification

#### 532 Binary traits (infertility)

533 Cases were identified in UK Biobank, Copenhagen Hospital Biobank and Danish Blood Donor 534 Study, deCode, Estonian Biobank, FinnGen, and Genes and Health (Supp. Text). We defined five 535 categories of female infertility: all causes (F-ALL), anovulatory (F-ANOV), anatomical (F-ANAT, 536 including tubal, uterine, and cervical origins), idiopathic infertility by exclusion of known causes 537 (anatomical and anovulatory infertility, PCOS, endometriosis, and uterine leiomyoma) (F-EXCL), 538 and idiopathic infertility by inclusion of a diagnosis code for idiopathic infertility (F-INCL), and male 539 infertility of all causes (M-ALL). Cases were identified through self-report (F-ALL, F-EXCL, M-ALL) 540 and through primary- and secondary-care codes (Supp. Table 1). Within each subtype, sex-541 matched controls were defined as individuals not identified as cases for that subtype.

542 Quantitative traits (reproductive hormones)

543 Hormones were included from UK Biobank, Avon Longitudinal Study of Parents and Children 544 (ALSPAC), deCode, Estonian Biobank, and Genes and Health (Supp. Text). We extracted 545 measurements of FSH, LH, oestradiol, progesterone, and testosterone from biobank assessment 546 centres or primary- and secondary-care records (Supp. Table 16). If repeated measurements 547 were available for an individual, we retained the recorded hormone value closest to the individual's median hormone value over time. Each hormone was regressed on age, age<sup>2</sup>, and cohort-specific 548 549 covariates specified below; the residuals from this regression were rank-based inverse normally 550 transformed (RINTed) prior to GWAS.

# 551 Meta-analysis of GWAS summary statistics

#### 552 Genome-wide association testing

553 Association analyses were performed separately within each ancestry and sex stratum for all 554 strata with at least 100 cases (binary traits) or 1,000 individuals (quantitative traits). For binary traits, each variant passing QC was tested for association under an additive model using 555 REGENIE<sup>107</sup> or SAIGE<sup>108</sup>, with adjustments for age, age<sup>2</sup>, and cohort-specific covariates, with the 556 Firth correction applied to control for inflation at rare variants and traits with low case-control 557 ratios<sup>107,108</sup>. For quantitative traits, the RINTed hormone value was tested for association under 558 an additive model using REGENIE<sup>107</sup> or SAIGE<sup>108</sup>, with adjustments for cohort-specific genetic 559 covariates. Any deviations from this GWAS protocol are noted in the Supplementary Text. 560

- 561 Meta-analysis
- 562 Prior to meta-analysis, summary statistics from all studies underwent thorough quality control to

retain variants that met the following criteria: (1) on the autosomes or X chromosome, (2) with

564 imputation information score >0.8 (where available), (3) bi-allelic variants with A, C, G, T alleles,

565 (4) with standard errors <10 and *P*-values in [0,1], and (5) without duplicate entries. Fixed-effects

- 566 inverse-variance weighted meta-analysis was performed using METAL<sup>109</sup>. We report results from
- 567 European-ancestry and all-ancestry meta-analyses for each trait. Genome-wide significance was
- 568 established at *P*<5E-08.

# <sup>569</sup> Identification and classification of lead variants

570 Distance-based pruning was used to identify lead variants as the SNP with the lowest *P*-value 571 within each 1Mb window at all loci with at least one GWS variant with P<5E-08.

572

573 Hormone-associated variants were classified based on conditional analysis as (1) previously 574 reported for the hormone of interest, (2) previously reported for any of 28 reproductive hormones, or (3) novel, based on SNP associations published in the GWAS Catalog as of 27 March 2023<sup>62</sup> 575 576 (Supp. Table 17). We adapted criteria developed by Benonisdottir et al. (2016)<sup>110</sup> to classify novel 577 variants as those that are not in LD with ( $r^2 < 0.1$ ), and conditionally independent of 578  $(P_{conditional} < 0.05)$ , all published hormone-associated variants within 1 Mb; all other variants are 579 considered to be previously reported. Conditional analysis was performed in GCTA-COJO<sup>111</sup>, with LD information for European-ancestry individuals derived from the 1000 Genomes dataset<sup>112</sup>. 580

581

For lead variants on the X chromosome and those from multi-ancestry analyses, for which estimating LD is more difficult due to differences in recombination rates and selection pressures between sexes and populations<sup>113–115</sup>, we did not use the above LD-based classification system. Instead, a lead SNP was considered novel if it was not within 1 Mb of a published hormoneassociated variant or if its effect was independent of published variants within a 1 Mb window ( $P_{conditional}$ <0.05), and reported if not.

# 588 SNP-based heritability

589 The following analyses, which rely on population-specific LD patterns, were restricted to European-ancestry summary statistics with pre-computed LD-scores based on European-590 ancestry individuals in the 1000 Genomes dataset<sup>112</sup>, restricted to HapMap3 SNPs<sup>52</sup>. We 591 estimated the SNP-based heritability ( $h_{g}^{2}$ ) of a trait from GWAS summary statistics using LD-592 593 score regression as implemented in the LDSC software<sup>51</sup>. For infertility traits, the observed-scale 594 heritability  $(h_{obs}^2)$  was converted to liability-scale heritability  $(h_{liab}^2)$ , which accounts for the disease prevalence in the sample (k) and population (K), under the assumption that sample prevalence 595 equals the population prevalence 54. 596

# 597 Genetic correlations

598 LDSC was used to estimate genetic correlations between infertility traits, hormone levels, and a 599 collection of other phenotypes in the UK Biobank in European-ancestry individuals. To simplify 600 computation of  $r_g$  across a large number of traits, we used an extension of the LDSC software 601 which allows for simultaneous estimation of multiple genetic correlations<sup>116</sup>.

602

603 We estimated genetic correlations among the three categories of female infertility with significant heritability (Z>4)<sup>51</sup>: F-ALL, F-ANOV, and F-INCL, as well as among heritable female reproductive 604 605 hormones (FSH and testosterone in females). We additionally obtained summary statistics from 606 GWASs of thyroid stimulating hormone (TSH)<sup>75</sup> (sex-combined analysis, N=247,107 participants) 607 and anti-Mullerian hormone (N=7,049 pre-menopausal participants)<sup>74</sup> from the largest publicly available European-ancestry studies to date. We also tested for genetic correlations between 608 609 infertility and reproductive hormones. Significant  $r_{\rm q}$  after multiple testing was established at 2.38E-610 03 (FWER controlled at 5% across 21 tests using the Bonferroni method).

611

612 We collated European-ancestry GWAS summary statistics for four female reproductive disorders: (1) endometriosis from Rahmioglu et al. (2023)<sup>35</sup>, (57,248 cases and 698,764 controls), (2) heavy 613 614 menstrual bleeding by meta-analysing GWAS data from Gallagher *et al.* (2019)<sup>117</sup> and FinnGen 615 data freeze 9<sup>27</sup> (31,309 cases and 318,510 controls), (3) PCOS by meta-analysing GWAS data from Tyrmi et al. (2022)<sup>92</sup> and a UKBB-based GWAS (14,467 cases and 430,267 controls), and 616 (4) uterine fibroids by meta-analysing GWAS data generated by the Neale lab<sup>53</sup> and FinnGen data 617 618 freeze 9<sup>27</sup>, (42,446 cases and 588,955 controls). We additionally obtained summary statistics 619 from a GWAS of spontaneous dizygotic (DZ) twinning (8.265 cases (mothers of DZ twins) and 620 264,567 controls; plus 26252 DZ twins and 417,433 additional controls) from Mbarek et al. (2024), 621 the largest European-ancestry study of female fecundity to date<sup>46</sup>. Significant  $r_g$  after multiple 622 testing was established at 2.00E-03 (FWER controlled at 5% across 25 tests using the Bonferroni 623 method).

624

625 We downloaded LD-score formatted summary statistics for European-ancestry individuals across 626 703 heritable phenotypes (*Z*>4) from the Neale lab round 2 collection<sup>53</sup>. The number of effectively 627 independent phenotypes estimated by the Neale lab ( $M_{eff}$ =340) was used to establish significant 628  $r_{g}$  after multiple testing at 2.45E-05 (FWER controlled at 5% across 2,040 tests using the 629 Bonferroni method).

#### 630 Mendelian randomisation

The following analyses were all performed with summary statistics from European-ancestry
 GWASs, using the TwoSampleMR v0.5.7 package<sup>118</sup>.

633

634 We constructed genetic instruments for BMI, WHR, and WHRadjBMI with female-specific lead 635 variants from a recent European-ancestry GWAS meta-analysis with a maximum sample size of 636 434,785 female participants<sup>67</sup>. SNPs were weighted by their female-specific effect sizes. The 637 mean F-statistic across all SNPs in each instrument indicated sufficient strength for MR

(BMI=61.3, WHR=74.8, WHRadiBMI=84.7, recommended>10<sup>119</sup>). As the instrument GWASs 638 639 included participants from UK Biobank, we conducted a sensitivity analysis to avoid bias from 640 sample overlap between instrument and outcome GWASs by constructing obesity-trait 641 instruments from an earlier release of summary statistics from the GIANT Consortium without 642 UKBB participants<sup>120</sup> (Supp. Table 11). As the WHRadjBMI instrument may be confounded due 643 to adjustment for a correlated variable<sup>121</sup>, i.e. adjustment for BMI in the WHR GWAS, we 644 performed multivariable MR with a joint instrument for BMI and WHR to estimate the BMI-adjusted 645 causal effect of WHR on reproductive outcomes. We found no difference in effect estimates from 646 MR conducted using an instrument for WHRadjBMI and multivariable MR (Supp. Table 19).

647

Hormone instruments were constructed for reproductive hormones in this study with F-statistic>10
 (FSH-F=38.7, testosterone-F=66.1), using GWAS summary statistics from European-ancestry
 GWASs excluding UK Biobank participants to avoid sample overlap with outcome GWASs.

651

We also performed reciprocal MR to test the genetically predicted causal effects of infertility on obesity and reproductive hormone levels. Genetic instruments were constructed for subtypes of infertility with F-statistic>10 (F-ALL=51.0, F-ANOV=36.2), using GWAS summary statistics from European-ancestry GWASs excluding UK Biobank participants to avoid sample overlap with outcome GWASs. We assessed the causal direction between each pair of traits tested with Steiger filtering of instruments and the Steiger directionality test.

658

659 We report results from the inverse-variance weighted (IVW) method, the MR-Egger method which 660 is robust to horizontal pleiotropy<sup>122</sup>, and the weighted median method which protects against 661 outlier variants<sup>123</sup> (Supp Table 11).

# 662 Colocalisation

663 The following analyses were all performed with summary statistics from European-ancestry 664 GWASs, using the Bayesian framework implemented in the coloc v5.1.0 package<sup>124</sup> under a single causal variant assumption<sup>125</sup>. Only common variants (MAF>1%) within windows of +/- 50 665 666 kb around each lead variant for an infertility or reproductive hormone trait were retained. For each 667 pair of traits tested for colocalisation, we set the prior probabilities of variants in a locus being 668 causally associated with trait 1 ( $p_1$ ) and trait 2 ( $p_2$ ) to 1E-04 (99% confidence in a true association). 669 and the prior for joint association p12 to 1E-06 (assuming equal likelihood of shared and non-670 shared causal variants for each trait in a locus) as recommended by the developers of coloc<sup>125</sup>. 671 We tested five hypotheses: H0=no association with either trait in region, H1=association with trait 672 1 in region, but not trait 2, H2=association with trait 2 in region, but not trait 1, H3=association 673 with both traits in region, but different causal variants, and H4=association with both traits in 674 region, and a shared causal variant. A pair of traits were considered to colocalise if posterior 675 probability of H4>50% and the ratio of posterior probabilities of H4/H3>5<sup>124,126</sup>.

676

677 We tested for colocalisation between each female infertility category and each female-specific 678 hormone (FSH, LH, oestradiol, and testosterone) at all genetic loci associated with at least one 679 of the pair of traits tested. The single male infertility locus with common variants (MAF>1%) in the 680 European-ancestry analysis did not contain enough significant associations (only 12 common 681 variants with P<1E-06) for colocalisation analyses.

682

Because we noticed that some lead variants for female infertility had previously been reported as associated with endometriosis and PCOS, we estimated the posterior probability (PP) of colocalisation of genetic signals between each category of female infertility and each of these two reproductive disorders. European-ancestry summary statistics for endometriosis and PCOS were obtained as described in the genetic correlations section above.

688

689 We assessed colocalisation of genetic signals for female infertility with eQTLs for all proximal 690 genes with transcription start sites (TSSs) within 1 Mb of an infertility lead variant. Publicly 601 available cOTL data was downloaded from the CTEx project<sup>41</sup>

691 available eQTL data was downloaded from the GTEx project<sup>41</sup>.

# 692 Tissue and cell-type prioritisation

693 We estimated the polygenic contributions of genes with tissue-specific expression profiles to the 694 heritability of infertility and hormones using stratified LD-score regression (partitioned heritability 695 analyses)<sup>51</sup>. We restricted these analyses to traits with highly significant heritability in European-696 ancestry analyses (Z>7) (F-ALL, testosterone-F, and testosterone-M), as recommended by the 697 developers, Finucane *et al.* (2015)<sup>127</sup>.

698

699 Gene sets and LD scores for 205 tissues and cell-types from the GTEx Project database<sup>41</sup> and 700 the Franke lab single-cell database<sup>72</sup> were downloaded from Finucane *et al.* (2018)<sup>128</sup>. We 701 established tissue-wide significance at -log10(*P*)>2.75, which corresponds to FDR<5%.

702 Ovarian cell types

703 As the ovary, a reproductive tissue of interest, is not well characterised in the GTEx project, we 704 identified two publicly available single-cell gene expression datasets for ovarian cell types: (1) 705 from Fan et al. (2019), who performed single-cell RNA sequencing on ovarian tissue from five 706 adult women undergoing fertility preservation procedures with 20,676 cells across 19 identified 707 cell types<sup>129</sup>, and (2) from Jin et al. (2022), who performed single-nucleus RNA sequencing on 708 autopsy samples from four women (aged 49-54 years, with normal ovarian histology) with 42,568 cells across 8 identified cell types<sup>130</sup>. The datasets were aligned and filtered using the QC 709 710 pipelines provided by the authors of each study, and clustered with identical parameters to replicate the results of each individual study. Gene sets for each cluster were identified as 711 recommended by Finucane *et al.* (2018)<sup>128</sup> - briefly, we identified differential expression between 712 713 the cells in each cluster and all other clusters by using the Wilcoxon rank sum test implemented 714 in Seurat v3.0<sup>131–133</sup>, and returned the top 10% of genes that are specifically expressed in each 715 cluster (positive average log-fold-change values), ranked by differential expression P-value. We 716 computed annotation-specific LD scores for these gene sets using hg38 coordinates for gene 717 TSSs and TESs obtained from Ensembl<sup>134</sup>, across 1 million HapMap3 variants<sup>52</sup> with LD 718 information from European-ancestry individuals in the 1000 Genomes phase 3 dataset<sup>112</sup>.

# 719 Overlaps with genetic regions under selection

To avoid confounding by population stratification, selection look-ups were restricted to GWAS
 summary statistics from European-ancestry individuals.

#### 722 Directional selection

723 Following guidelines described by Mathieson et al. (2023)<sup>25</sup>, we identified 54 genomic regions 724 under directional selection from three previously reported genome-wide scans: (1) 39 regions 725 from the Composite of Multiple Signals (CMS) test, which infers historical selection on the order of the past 50,000 years<sup>58</sup>, (2) 12 regions from an ancient DNA scan that uses inferences of allele 726 727 frequency from ancient genomes to determine selection over the past 10,000 years<sup>57</sup>, and (3) 728 three regions from Singleton Density Scores (SDSs), which use the pattern of singleton variants to identify recent selection in the past 2,000 to 3,000 years<sup>56</sup>. For each genomic window under 729 730 directional selection, we report the infertility-associated variants with the lowest P-value.

#### 731 Singleton density scores

We downloaded publicly available SDSs for SNPs in the UK10K dataset<sup>56</sup> to report the highest 732 733 SDS (positive selection of derived allele over ancestral allele in the past 2,000 to 3,000 years) 734 and lowest SDS (negative selection) within the +/-10kb window around each infertility or hormone 735 lead SNP. To calculate trait-SDS for each phenotype, we aligned each SDS to the trait-increasing allele rather than the derived allele<sup>56</sup>. For each lead variant window containing variants with 736 extreme SDSs (top 97.5th %ile or bottom 2.5th %ile), we report the direction of selection with 737 738 respect to the trait-increasing allele. Percentiles of SDSs were evaluated only on a subset of 739 variants within 10kb of any variant reported in the GWAS Catalog to account for genomic context. 740 Further, as variants that are sub-GWS for a trait may nonetheless be under selection, we 741 calculated the genome-wide mean trait-SDS in each bin of 1000 variants, ranked by P-value for 742 the trait association, following the protocol outlined by Field *et al.* (2016)<sup>56</sup>.

#### 743 Balancing selection

We accessed publicly available standardised BetaScan2 scores, which detect balancing selection using polymorphism and substitution data, for all SNPs in the 1000 Genomes dataset<sup>59</sup>. We tested whether the +/-10kb window around each infertility or hormone lead variant contained SNPs with scores in the 99th %ile of standardised BetaScan2 scores. Percentiles of SDSs were evaluated only on a subset of variants within 10kb of any variant reported in the GWAS Catalog to account for genomic context. For each lead variant window, we report the highest standardised BetaScan2 score and its percentile.

# 751 Whole exome sequencing analyses in the UK Biobank

#### 752 Exome sequencing quality control

#### 753 Quality control outline

754 We first considered an initial set of "high quality" variants to evaluate the mean call rate and depth 755 of coverage for each sample. We then ran a sample and variant level pre-filtering step and 756 calculated sample-level QC metrics. Using these metrics, we removed sample outliers based on 757 median absolute deviation (MAD) thresholds, and excluded sites which did not pass variant QC 758 according to Karzcewski et al. (2022)<sup>135</sup>. We then applied a genotype-level filter using genotype 759 quality (GQ), depth (DP), and heterozygote allele balance (AB). The resultant high-quality 760 European call set consisted of 402.375 samples and 25.229.669 variants. For details see 761 Supplementary Text.

#### 762 Variant annotation

763 We annotated variants using Variant Effect Predictor (VEP) v105 (corresponding to gencode v39)<sup>136</sup> with the LOFTEE v1.04 GRCh38<sup>137</sup> and dbNSFP<sup>138</sup> plugins, annotating variants with 764 CADD v1.6<sup>139</sup>, and REVEL using dbNSFP4.3<sup>140</sup> and loss of function confidence using LOFTEE. 765 Complete instructions and code for this step are provided in our VEP 105 LOFTEE repository<sup>141</sup>, 766 767 which contains a docker/singularity container to ensure reproducibility of annotations. We then 768 ran SpliceAI v1.3<sup>142</sup> using the gencode v39 gene annotation file to ensure alignment between 769 VEP and SpliceAl transcript annotations. We defined 'canonical' transcripts to be used for variant-770 specific annotations as follows: set MANE Select<sup>143</sup> as the canonical, where available, and if a 771 MANE Select transcript is not present, set canonical and restrict to protein coding genes. Note 772 that for VEP 105, this is equivalent to selecting the 'canonical' transcript in protein coding genes. 773 Then, using the collection of missense, pLoF, splice metrics, and annotations of variant 774 consequence on the 'canonical' transcript, we determine a set of variant categories for gene-775 based testing.

- 776 Variant categories for gene-based tests
- 1. High confidence pLoF: high-confidence LoF variants, as defined by LOFTEE <sup>137</sup>
   (LOFTEE HC).
- 2. **Damaging missense/protein-altering**: at least one of:
- 780 781

782

783

784

785

- a. Variant annotated as missense/start-loss/stop-loss/in-frame indel and (REVEL≥0.773 or CADD≥28.1 (or both)).
- b. Any variant with SpliceAI delta score (DS)≥0.2 where SpliceAI DS the maximum of the set {DS\_AG, DS\_AL, DS\_DG, DS\_DL} for each annotated variant (where DS\_AG, DS\_AL, DS\_DG and DS\_DL are delta score (acceptor gain), delta score (acceptor loss), delta score (donor gain), and delta score (donor loss), respectively).
- 787 c. Low-confidence LoF variants, as defined by LOFTEE (LOFTEE LC)
- 788 3. Other missense/protein-altering:

- 789 Missense/start-loss/stop-loss/in-frame indel not categorised in (2) (Damaging 790 missense/protein-altering).
  - 4. **Synonymous**: synonymous variants with SpliceAI DS<0.2 in the gene (our 'control' set).
- 791 792

REVEL and CADD score cut-offs are chosen to reflect the supporting level for pathogenicity (PP3)

REVEL and CADD score cut-offs are chosen to reflect the supporting level for pathogenicity (PP3)
 from the American College of Medical Genetics and Genomics and the Association for Molecular
 Pathology (ACMG/AMP) criteria<sup>144</sup>.

796

Variant counts and average allele counts for each annotation, split by population label and binnedby MAF are displayed in Supp. Figure 13 and Supp. Figure 14, respectively.

#### 799 Genetic association testing

800 We carried out rare variant genetic association testing in the European-ancestry subset of the UK 801 Biobank using Scalable and Accurate Implementation of GEneralized mixed model (SAIGE) <sup>108</sup>. 802 a mixed model framework that accounts for sample relatedness and case-control imbalance 803 through a saddle-point approximation in binary traits. All rare-variant analysis was carried out on 804 the UK Biobank Research Analysis Platform (RAP) using SAIGE version wzhou88/saige:1.1.9<sup>108</sup>. 805 In the sex-combined analyses, we account for age, sex, age<sup>2</sup>, age × sex, age<sup>2</sup> × sex, and the first 806 10 genetic principal components as fixed effects; and age, age<sup>2</sup>, and the first 10 principal 807 components in sex-specific analyses. All continuous traits were inverse rank normalised prior to 808 association testing.

809

For SAIGE step 0, we constructed a genetic relatedness matrix (GRM) using the UK Biobank genotyping array data. We LD pruned the genotyped data using PLINK (--indep-pairwise 50 5 0.05)<sup>145</sup>, and created a sparse GRM using 5000 randomly selected markers, with relatedness cutoff of 0.05, using the createSparseGRM.R function within SAIGE. To generate a variance ratio file for subsequent steps in SAIGE, we extracted 1000 variants each with MAC<20 and MAC>20, and combined these markers to define a PLINK file for the variance ratio determination.

817

In SAIGE step 1 for each trait, the curated phenotype data and sparse GRM were used to fit a
 null model with no genetic contribution. All parameters were set at the defaults in SAIGE, except
 --relatednessCutoff 0.05, --useSparseGRMtoFitNULL TRUE and - isCateVarianceRatio TRUE. Tolerance for fitting the null generalised linear mixed model
 was set to 0.00001.

823 Rare variant and gene based testing

824 Following null model fitting, we carried out variant and gene-based testing in SAIGE step 2 using the variant categories described above, with the --is single in groupTest TRUE flag. All 825 826 parameters to default, other were set except \_\_\_ 827 maxMAF in groupTest=0.0001,0.001,0.01, --is Firth beta TRUE, \_\_\_ 828 pCutoffforFirth=0.1, and --is fastTest TRUE. We included the following collection of

829	group	tests,	using	the	annotations	defined	in	methods:	variant	annotation.	
830											
831	•	High cor	nfidence	pLoF							
832	•	Damaging missense/protein-altering									
833	•	Other missense/protein-altering									
834	•	Synonymous									
835	•	High confidence pLoF or Damaging missense/protein-altering									
836	•	High confidence pLoF or Damaging missense/protein-altering or Other missense/protein-									
837		altering	or Synon	ymous	6						
838											
839	We the	en carried	l out Cau	ichy co	mbination test	s <sup>146</sup> across	thes	e annotation	s for each	gene.	

#### 840 Data and code availability

841 Cohorts may be contacted individually for access to raw data. Summary statistics for all 842 phenotypes will be made available through the GWAS Catalog upon publication. All code used in 843 this study will be made available through GitHub upon publication.

## 844 Acknowledgements

845 Thanks to Prof Pier Palamara and Prof Zoltan Kutalik for helpful discussions. We are grateful to 846 the participants of all cohorts. This research has partly been conducted using the UK Biobank 847 Resource under Application Number 11867. Genes & Health is/has recently been core-funded by 848 Wellcome (WT102627, WT210561), the Medical Research Council (UK) (M009017, 849 MR/X009777/1, MR/X009920/1), Higher Education Funding Council for England Catalyst, Barts 850 Charity (845/1796), Health Data Research UK (for London substantive site), and research delivery 851 support from the NHS National Institute for Health Research Clinical Research Network (North 852 Thames). Genes & Health is/has recently been funded by Alnylam Pharmaceuticals, Genomics 853 PLC; and a Life Sciences Industry Consortium of Astra Zeneca PLC, Bristol-Myers Squibb 854 Company, GlaxoSmithKline Research and Development Limited, Maze Therapeutics Inc, Merck 855 Sharp & Dohme LLC, Novo Nordisk A/S, Pfizer Inc, Takeda Development Centre Americas Inc. 856 We thank Social Action for Health, Centre of The Cell, members of our Community Advisory 857 Group, and staff who have recruited and collected data from volunteers. We thank the NIHR 858 National Biosample Centre (UK Biocentre), the Social Genetic & Developmental Psychiatry 859 Centre (King's College London), Wellcome Sanger Institute, and Broad Institute for sample 860 processing, genotyping, sequencing and variant annotation. We thank: Barts Health NHS Trust, 861 NHS Clinical Commissioning Groups (City and Hackney, Waltham Forest, Tower Hamlets, 862 Newham, Redbridge, Havering, Barking and Dagenham), East London NHS Foundation Trust, 863 Bradford Teaching Hospitals NHS Foundation Trust, Public Health England (especially David 864 Wyllie), Discovery Data Service/Endeavour Health Charitable Trust (especially David Stables), 865 Voror Health Technologies Ltd (especially Sophie Don), NHS England (for what was NHS Digital) 866 - for GDPR-compliant data sharing backed by individual written informed consent. Most of all we 867 thank all of the volunteers participating in Genes & Health. This study was funded by the European 868 Union through the European Regional Development Fund Project No. 2014-2020.4.01.15-0012

869 GENTRANSMED. Data analysis was carried out in part in the High-Performance Computing 870 Center of University of Tartu. This research has partly been conducted using the ALSPAC 871 resource under Project Number B4568. The activities of the EstBB are regulated by the Human 872 Genes Research Act, which was adopted in 2000 specifically for the operations of the EstBB. 873 Individual level data analysis in the EstBB was carried out under ethical approval 1.1-12/624 from 874 the Estonian Committee on Bioethics and Human Research (Estonian Ministry of Social Affairs), 875 using data according to release application 3-10/GI/10790 from the Estonian Biobank. This study 876 was funded by the Estonian Research Council grants PRG1911. We want to acknowledge the 877 participants and investigators of the FinnGen study. The FinnGen project is funded by two grants 878 from Business Finland (HUS 4685/31/2016 and UH 4386/31/2016) and the following industry 879 partners: AbbVie Inc., AstraZeneca UK Ltd, Biogen MA Inc., Bristol Myers Squibb (and Celgene 880 Corporation & Celgene International II Sarl), Genentech Inc., Merck Sharp & Dohme LCC, Pfizer 881 Inc., GlaxoSmithKline Intellectual Property Development Ltd., Sanofi US Services Inc., Maze 882 Therapeutics Inc., Janssen Biotech Inc, Novartis Pharma AG, and Boehringer Ingelheim 883 International GmbH. Following biobanks are acknowledged for delivering biobank samples to 884 FinnGen: Auria Biobank (www.auria.fi/biopankki), THL Biobank (www.thl.fi/biobank), Helsinki 885 Biobank (www.helsinginbiopankki.fi), Biobank **Borealis** of Northern Finland 886 (https://www.ppshp.fi/Tutkimus-ja-opetus/Biopankki/Pages/Biobank-Borealis-briefly-in-

887 English.aspx), Finnish Clinical Biobank Tampere (www.tays.fi/en-888 US/Research and development/Finnish Clinical Biobank Tampere), Biobank of Eastern 889 Central Finland Biobank (www.ita-suomenbiopankki.fi/en), (www.ksshp.fi/fi-Finland 890 FI/Potilaalle/Biopankki), Finnish Red Cross Blood Service Biobank 891 (www.veripalvelu.fi/verenluovutus/biopankkitoiminta), Terveystalo Biobank 892 (www.terveystalo.com/fi/Yritystietoa/Terveystalo-Biopankki/Biopankki/) and Arctic Biobank 893 (https://www.oulu.fi/en/university/faculties-and-units/faculty-medicine/northern-finland-birth-

894 cohorts-and-arctic-biobank). All Finnish Biobanks are members of BBMRI.fi infrastructure 895 (www.bbmri.fi). Finnish Biobank Cooperative -FINBB (https://finbb.fi/) is the coordinator of 896 BBMRI-ERIC operations in Finland. The Finnish biobank data can be accessed through the 897 Fingenious® services (https://site.fingenious.fi/en/) managed by FINBB. We are extremely 898 grateful to all the families who took part in this study, the midwives for their help in recruiting them, 899 and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, 900 clerical workers, research scientists, volunteers, managers, receptionists and nurses. We 901 acknowledge the contribution of the participants in the deCODE study. Patients and control 902 subjects in FinnGen provided informed consent for biobank research, based on the Finnish 903 Biobank Act. Alternatively, separate research cohorts, collected prior the Finnish Biobank Act 904 came into effect (in September 2013) and start of FinnGen (August 2017), were collected based 905 on study-specific consents and later transferred to the Finnish biobanks after approval by Fimea 906 (Finnish Medicines Agency), the National Supervisory Authority for Welfare and Health. 907 Recruitment protocols followed the biobank protocols approved by Fimea. The Coordinating 908 Ethics Committee of the Hospital District of Helsinki and Uusimaa (HUS) statement number for 909 the FinnGen study is Nr HUS/990/2017. The FinnGen study is approved by Finnish Institute for 910 Health and Welfare (permit numbers: THL/2031/6.02.00/2017, THL/1101/5.05.00/2017, 911 THL/341/6.02.00/2018, THL/2222/6.02.00/2018, THL/283/6.02.00/2019, THL/1721/5.05.00/2019 912 and THL/1524/5.05.00/2020), Digital and population data service agency (permit numbers:

913 VRK43431/2017-3, VRK/6909/2018-3, VRK/4415/2019-3), the Social Insurance Institution 914 (permit numbers: KELA 58/522/2017, KELA 131/522/2018, KELA 70/522/2019, KELA 98/522/2019, KELA 134/522/2019, KELA 138/522/2019, KELA 2/522/2020, KELA 16/522/2020), 915 916 numbers THL/2364/14.02/2020. THL/4055/14.06.00/2020. Findata permit 917 THL/3433/14.06.00/2020, THL/4432/14.06/2020, THL/5189/14.06/2020. 918 THL/5894/14.06.00/2020. THL/6619/14.06.00/2020, THL/209/14.06.00/2021, 919 THL/688/14.06.00/2021, THL/1284/14.06.00/2021, THL/1965/14.06.00/2021, 920 THL/5546/14.02.00/2020, THL/2658/14.06.00/2021, THL/4235/14.06.00/2021, Statistics Finland 921 (permit numbers: TK-53-1041-17 and TK/143/07.03.00/2020 (earlier TK-53-90-20) 922 TK/1735/07.03.00/2021, TK/3112/07.03.00/2021) and Finnish Registry for Kidney Diseases permission/extract from the meeting minutes on 4th July 2019. The Biobank Access Decisions for 923 924 FinnGen samples and data utilised in FinnGen Data Freeze 10 include: THL Biobank BB2017\_55, BB2017\_111, BB2018\_19, BB\_2018\_34, BB\_2018\_67, BB2018\_71, BB2019\_7, 925 926 BB2019 8, BB2019 26, BB2020 1, BB2021 65, Finnish Red Cross Blood Service Biobank 927 7.12.2017, Helsinki Biobank HUS/359/2017, HUS/248/2020, HUS/150/2022 § 12, §13, §14, §15, 928 §16, §17, §18, and §23, Auria Biobank AB17-5154 and amendment #1 (August 17 2020) and 929 amendments BB 2021-0140, BB 2021-0156 (August 26 2021, Feb 2 2022), BB 2021-0169, 930 BB 2021-0179, BB 2021-0161, AB20-5926 and amendment #1 (April 23 2020)and it's 931 modification (Sep 22 2021), Biobank Borealis of Northern Finland 2017 1013, 2021 5010, 932 2021 5018, 2021 5015, 2021 5023, 2021 5017, 2022 6001, Biobank of Eastern Finland 933 1186/2018 and amendment 22 § /2020, 53§/2021, 13§/2022, 14§/2022, 15§/2022, Finnish 934 Clinical Biobank Tampere MH0004 and amendments (21.02.2020 & 06.10.2020), §8/2021, 935 §9/2022, §10/2022, §12/2022, §20/2022, §21/2022, §22/2022, §23/2022, Central Finland 936 Biobank 1-2017, and Terveystalo Biobank STB 2018001 and amendment 25th Aug 2020, Finnish 937 Hematological Registry and Clinical Biobank decision 18th June 2021, Arctic biobank P0844: 938 ARC 2021 1001. We want to acknowledge the participants and investigators of FinnGen study. 939 The FinnGen project is funded by two grants from Business Finland (HUS 4685/31/2016 and UH 940 4386/31/2016) and the following industry partners: AbbVie Inc., AstraZeneca UK Ltd, Biogen MA 941 Inc., Bristol Myers Squibb (and Celgene Corporation & Celgene International II Sarl), Genentech Inc., Merck Sharp & Dohme LCC, Pfizer Inc., GlaxoSmithKline Intellectual Property Development 942 943 Ltd., Sanofi US Services Inc., Maze Therapeutics Inc., Janssen Biotech Inc, Novartis Pharma AG, 944 and Boehringer Ingelheim International GmbH. Following biobanks are acknowledged for 945 delivering biobank samples to FinnGen: Auria Biobank (www.auria.fi/biopankki), THL Biobank 946 (www.thl.fi/biobank), Helsinki Biobank (www.helsinginbiopankki.fi), Biobank Borealis of Northern 947 Finland (https://www.ppshp.fi/Tutkimus-ja-opetus/Biopankki/Pages/Biobank-Borealis-briefly-in-948 English.aspx), Finnish Clinical Biobank Tampere (www.tays.fi/en-949 Biobank US/Research and development/Finnish Clinical Biobank Tampere), of Eastern 950 (www.ita-suomenbiopankki.fi/en), Central Finland Biobank Finland (www.ksshp.fi/fi-951 FI/Potilaalle/Biopankki), Finnish Red Cross Blood Service Biobank 952 (www.veripalvelu.fi/verenluovutus/biopankkitoiminta), Terveystalo Biobank 953 (www.terveystalo.com/fi/Yritystietoa/Terveystalo-Biopankki/Biopankki/) and Biobank Arctic 954 (https://www.oulu.fi/en/university/faculties-and-units/faculty-medicine/northern-finland-birth-955 cohorts-and-arctic-biobank). All Finnish Biobanks are members of BBMRI.fi infrastructure 956 (www.bbmri.fi). Finnish Biobank Cooperative -FINBB (https://finbb.fi/) is the coordinator of BBMRI-ERIC operations in Finland. The Finnish biobank data can be accessed through the
Fingenious® services (https://site.fingenious.fi/en/) managed by FINBB. This study was based on
the CHB reproduction protocol and DBDS (ethical approval NVK-1805807; NVK-1700407; SJ740).

# 961 Funding Statement

962 S.S.V. is supported by the Rhodes Scholarships, Clarendon Fund, and the Medical Sciences
963 Doctoral Training Centre at the University of Oxford. L.B.L.W. was supported by the Wellcome
964 Trust. B.M.J. is funded by an Medical Research Council (MRC) Clinical

965 Research Training Fellowship (CRTF) jointly supported by the UK MS Society (B.M.J.;

grant reference: MR/V028766/1). A.P. is supported by Alma and K.A. Snellman Foundation.

967 Genes & Health is/has recently been core-funded by Wellcome (WT102627, WT210561), the 968 Medical Research Council (UK) (M009017, MR/X009777/1, MR/X009920/1), Higher Education 969 Funding Council for England Catalyst, Barts Charity (845/1796), Health Data Research UK (for 970 London substantive site), and research delivery support from the NHS National Institute for Health 971 Research Clinical Research Network (North Thames). A.E. and D.A.L contributions are supported 972 by the UK Medical Research Council (MC UU 00032/05) and the European Research Council 973 under the European Union's Horizon 2020 research and innovation program (grant agreements 974 No 101021566). Genes & Health is/has recently been funded by Alnylam Pharmaceuticals, 975 Genomics PLC; and a Life Sciences Industry Consortium of Astra Zeneca PLC, Bristol-Myers 976 Squibb Company, GlaxoSmithKline Research and Development Limited, Maze Therapeutics Inc, 977 Merck Sharp & Dohme LLC, Novo Nordisk A/S, Pfizer Inc, Takeda Development Centre Americas 978 Inc. The UK Medical Research Council and Wellcome (Grant ref: 217065/Z/19/Z) and the 979 University of Bristol provide core support for ALSPAC. A comprehensive list of grants funding is 980 available on the ALSPAC website (http://www.bristol.ac.uk/alspac/external/documents/grant-981 acknowledgements.pdf). Genome-wide genotyping data was generated by Sample Logistics and 982 Genotyping Facilities at Wellcome Sanger Institute and LabCorp (Laboratory Corporation of 983 America) using support from 23andMe. C.M.L. is supported by the Li Ka Shing Foundation, NIHR 984 Oxford Biomedical Research Centre, Oxford, NIH (1P50HD104224-01), Gates Foundation (INV-985 024200), and a Wellcome Trust Investigator Award (221782/Z/20/Z). The research was supported 986 by the Wellcome Trust Core Award Grant Number 203141/Z/16/Z with additional support from the 987 NIHR Oxford BRC. The views expressed are those of the authors and not necessarily those of 988 the NHS, the NIHR or the Department of Health.

#### 989 Competing Interests Statement

L.B.L.W. is currently employed by Novo Nordisk Research Centre Oxford but, while she
conducted the research described in this manuscript, was only affiliated to the University of
Oxford. V.S., G.T., H.H., I.J., and K.S. are employees of deCODE genetics, a subsidiary of
Amgen. C.M.L. reports grants from Bayer AG and Novo Nordisk and has a partner who works at
Vertex. The other authors declare no conflicts of interest.

### 995 Supplementary Author List

996 Genes & Health Research Team: Shaheen Akhtar, Mohammad Anwar, Elena Arciero, Omar 997 Asgar, Samina Ashraf, Saeed Bidi, Gerome Breen, James Broster, Raymond Chung, David 998 Collier, Charles J Curtis, Shabana Chaudhary, Megan Clinch, Grainne Colligan, Panos Deloukas, 999 Ceri Durham, Faiza Durrani, Fabiola Eto, Sarah Finer, Joseph Gafton, Ana Angel, Chris Griffiths, 1000 Joanne Harvey, Teng Heng, Sam Hodgson, Qin Qin Huang, Matt Hurles, Karen A Hunt, Shapna 1001 Hussain, Kamrul Islam, Vivek Iyer, Benjamin M Jacobs, Ahsan Khan, Claudia Langenberg, Cath 1002 Lavery, Sang Hyuck Lee, Daniel MacArthur, Sidra Malik, Daniel Malawsky, Hilary Martin, Dan 1003 Mason, Rohini Mathur, Mohammed Bodrul Mazid, John McDermott, Caroline Morton, Bill 1004 Newman, Elizabeth Owor, Asma Qureshi, Shwetha Ramachandrappa, Mehru Raza, Jessry 1005 Russell, Nishat Safa, Miriam Samuel, Michael Simpson, John Solly, Marie Spreckley, Daniel 1006 Stow, Michael Taylor, Richard C Trembath, Karen Tricker, David A van Heel, Klaudia Walter, 1007 Caroline Winckley, Suzanne Wood, John Wright, Ishevanhu Zengeva, Julia Zöllner.

1008 Estonian Biobank Research Team: Andres Metspalu, Lili Milani, Tõnu Esko, Mari Nelis and 1009 Georgi Hudjashov.

- 1010 Estonian Health Information Research Team: Raivo Kolde, Sven Laur, Sulev Reisberg and Jaak1011 Vilo.
- 1012

1013 DBDS Genomic Consortium: Agnete Lundgaard; Alexander Pil Henriksen; Bertram Dalskov 1014 Kierulff: Bitten Aagaard Jensen: Biarke Feenstra: Christian Erikstrup: Christina Mikkelsen: Daniel 1015 Gudbjartsson; David Westergaard; Erik Sørensen; Frank Geller; Gregor Jemec; Henrik Hjalgrim; 1016 Henrik Ullum; Hreinn Stefánsson; Ioanna Nissen; Ioannis Louloudis ; Jakob Bay; Jens Kjærgaard 1017 Boldsen; Joseph Dowsett; Kari Stefansson; Karina Banasik; Katrine Kaspersen; Khoa Manh Dinh; 1018 Klaus Rostgaard; Kristoffer Burgdorf; Lise Wegner Thørner; Lisette Kogelman; Lotte Hindhede; 1019 Margit Anita Hørup Larsen; Maria Didriksen; Mette Nyegaard; Michael Schwinn; Mie Topholm 1020 Bruun; Mona Ameri Chalmer; Ole Birger Pedersen; Palle Duun Rohde; Rikke Louise Jacobsen; 1021 Sisse Rye Ostrowski; Søren Brunak; Susan Mikkelsen; Thomas Folkmann Hansen; Thomas 1022 Werge; Thorsten Brodersen; Unnur Þorsteinsdóttir.

- 1023
- 1024 FinnGen: See separate document.

#### 1025 References

- 1026 1. Infertility prevalence estimates, 1990–2021.
- 1027 https://www.who.int/publications/i/item/978920068315 (2023).
- Brandt, J. S., Cruz Ithier, M. A., Rosen, T. & Ashkinadze, E. Advanced paternal age, infertility, and reproductive risks: A review of the literature. *Prenat. Diagn.* **39**, 81–87 (2019).
- 1030 3. Crawford, N. M. & Steiner, A. Z. Age-related infertility. *Obstet. Gynecol. Clin. North Am.* 42, 15–25 (2015).
- Tsevat, D. G., Wiesenfeld, H. C., Parks, C. & Peipert, J. F. Sexually transmitted diseases and infertility. *Am. J. Obstet. Gynecol.* **216**, 1–9 (2017).
- Passos, L. G. *et al.* The Correlation between Chlamydia Trachomatis and Female Infertility:
   A Systematic Review. *Rev. Bras. Ginecol. Obstet.* 44, 614–620 (2022).
- Tjahyadi, D. *et al.* Female Genital Tuberculosis: Clinical Presentation, Current Diagnosis, and Treatment. *Infect. Dis. Obstet. Gynecol.* **2022**, 3548190 (2022).
- Shteinberg, M., Taylor-Cousar, J. L., Durieu, I. & Cohen-Cymberknoh, M. Fertility and Pregnancy in Cystic Fibrosis. *Chest* 160, 2051–2060 (2021).
- 1040 8. Jarzabek, K. *et al.* Cystic fibrosis as a cause of infertility. *Reprod. Biol.* **4**, 119–129 (2004).
- Matzuk, M. M. & Lamb, D. J. The biology of infertility: research advances and clinical challenges. *Nat. Med.* 14, 1197–1213 (2008).
- 1043 10. Krausz, C. & Riera-Escamilla, A. Genetics of male infertility. *Nat. Rev. Urol.* **15**, 369–384 (2018).
- 1045
  11. Payne, N. & van den Akker, O. Mental health and coping with fertility treatment cessation
  1046
  1047
  1047
  1047
  1048
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  1049
  10
- 1048 12. Kwan, I., Wang, R., Pearce, E. & Bhattacharya, S. Pain relief for women undergoing oocyte 1049 retrieval for assisted reproduction. *Cochrane Database Syst. Rev.* **5**, CD004829 (2018).
- 13. Katz, P. *et al.* Costs of infertility treatment: results from an 18-month prospective cohort
   study. *Fertil. Steril.* **95**, 915–921 (2011).
- 14. Lai, J. D. *et al.* Unmet financial burden of infertility care and the impact of state insurance
  mandates in the United States: analysis from a popular crowdfunding platform. *Fertil. Steril.*1054
  116, 1119–1125 (2021).
- 1055 15. Bonavina, G. & Taylor, H. S. Endometriosis-associated infertility: From pathophysiology to
   1056 tailored treatment. *Front. Endocrinol.* 13, 1020827 (2022).
- 1057 16. Hoeger, K. M., Dokras, A. & Piltonen, T. Update on PCOS: Consequences, Challenges, 1058 and Guiding Treatment. *J. Clin. Endocrinol. Metab.* **106**, e1071–e1083 (2021).
- 17. Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus
   on infertility treatment related to polycystic ovary syndrome. *Hum. Reprod.* 23, 462–477
   (2008).
- 1062 18. Vannuccini, S. *et al.* Infertility and reproductive disorders: impact of hormonal and
  1063 inflammatory mechanisms on pregnancy outcome. *Hum. Reprod. Update* 22, 104–115
  1064 (2016).
- 1065 19. Concepción-Zavaleta, M. *et al.* Assessment of hormonal status in male infertility. An update. *Diabetes Metab. Syndr.* **16**, 102447 (2022).
- 1067 20. Silvestris, E., de Pergola, G., Rosania, R. & Loverro, G. Obesity as disruptor of the female
   1068 fertility. *Reprod. Biol. Endocrinol.* 16, 22 (2018).
- 1069 21. A life-course approach to women's health. *Nat. Med.* **30**, 1 (2024).
- 1070 22. Eisenberg, M. L. et al. Male infertility. Nat Rev Dis Primers 9, 49 (2023).
- 1071 23. Gardner, D. K. & Sakkas, D. Making and selecting the best embryo in the laboratory. *Fertil.* 1072 *Steril.* 120, 457–466 (2023).
- 1073 24. Barban, N. et al. Genome-wide analysis identifies 12 loci influencing human reproductive

- 1074 behavior. *Nat. Genet.* **48**, 1462–1472 (2016).
- 1075 25. Mathieson, I. *et al.* Genome-wide analysis identifies genetic effects on reproductive
  1076 success and ongoing natural selection at the FADS locus. *Nat Hum Behav* 7, 790–801
  1077 (2023).
- 1078 26. Hakonarson, H., Gulcher, J. R. & Stefansson, K. deCODE genetics, Inc.
  1079 *Pharmacogenomics* 4, 209–215 (2003).
- 1080 27. Kurki, M. I. *et al.* FinnGen provides genetic insights from a well-phenotyped isolated population. *Nature* **613**, 508–518 (2023).
- 1082 28. Heyne, H. O. *et al.* Mono- and biallelic variant effects on disease at biobank scale. *Nature*1083 613, 519–525 (2023).
- Wicherek, L. *et al.* The placental RCAS1 expression during stillbirth. *Reprod. Biol. Endocrinol.* 3, 24 (2005).
- 30. Ohshima, K., Nakashima, M., Sonoda, K., Kikuchi, M. & Watanabe, T. Expression of
  RCAS1 and FasL in human trophoblasts and uterine glands during pregnancy: the possible
  role in immune privilege. *Clin. Exp. Immunol.* **123**, 481–486 (2001).
- 1089 31. Zhang, G. *et al.* Genetic Associations with Gestational Duration and Spontaneous Preterm
   1090 Birth. *N. Engl. J. Med.* 377, 1156–1167 (2017).
- 1091 32. Välimäki, N. *et al.* Genetic predisposition to uterine leiomyoma is determined by loci for genitourinary development and genome stability. *Elife* **7**, (2018).
- 1093 33. Rafnar, T. *et al.* Variants associating with uterine leiomyoma highlight genetic background 1094 shared by various cancers and hormone-related traits. *Nat. Commun.* **9**, 3636 (2018).
- 1095 34. Luong, H. T. *et al.* Fine mapping of variants associated with endometriosis in the WNT4 1096 region on chromosome 1p36. *Int. J. Mol. Epidemiol. Genet.* **4**, 193–206 (2013).
- 1097 35. Rahmioglu, N. *et al.* The genetic basis of endometriosis and comorbidity with other pain 1098 and inflammatory conditions. *Nat. Genet.* **55**, 423–436 (2023).
- 36. Pellegrino, M., Maiorino, R. & Schonauer, S. WNT4 signaling in female gonadal development. *Endocr. Metab. Immune Disord. Drug Targets* 10, 168–174 (2010).
- 37. Bernard, P. & Harley, V. R. Wnt4 action in gonadal development and sex determination. *Int. J. Biochem. Cell Biol.* **39**, 31–43 (2007).
- 38. Pitzer, L. M., Moroney, M. R., Nokoff, N. J. & Sikora, M. J. WNT4 Balances Development vs
  Disease in Gynecologic Tissues and Women's Health. *Endocrinology* 162, (2021).
- 39. Groza, T. *et al.* The International Mouse Phenotyping Consortium: comprehensive knockout
  phenotyping underpinning the study of human disease. *Nucleic Acids Res.* **51**, D1038–
  D1045 (2023).
- 40. Ochoa, D. *et al.* The next-generation Open Targets Platform: reimagined, redesigned, rebuilt. *Nucleic Acids Res.* 51, D1353–D1359 (2023).
- 41. GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. *Nat. Genet.* 45, 580–
  585 (2013).
- 42. Ying, S. Y. Inhibins and activins: chemical properties and biological activity. *Proc. Soc. Exp.*Biol. Med. 186, 253–264 (1987).
- 43. Chada, M. *et al.* Inhibin B, follicle stimulating hormone, luteinizing hormone, and estradiol and their relationship to the regulation of follicle development in girls during childhood and puberty. *Physiol. Res.* 52, 341–346 (2003).
- 1117 44. Nawaz, S. *et al.* A variant in sperm-specific glycolytic enzyme enolase 4 (ENO4) causes
  1118 human male infertility. *J. Gene Med.* e3583 (2023).
- 1119 45. Nakamura, N. *et al.* Disruption of a spermatogenic cell-specific mouse enolase 4 (eno4) 1120 gene causes sperm structural defects and male infertility. *Biol. Reprod.* **88**, 90 (2013).
- 46. Mbarek, H. *et al.* Genome-wide association study meta-analysis of dizygotic twinning illuminates genetic regulation of female fecundity. *Hum. Reprod.* **39**, 240–257 (2024).
- 47. Paskulin, D. D., Cunha-Filho, J. S., Paskulin, L. D., Souza, C. A. B. & Ashton-Prolla, P.
   ESR1 rs9340799 is associated with endometriosis-related infertility and in vitro fertilization

- 1125 failure. *Dis. Markers* **35**, 907–913 (2013).
- 48. Wang, W. *et al.* Association of an oestrogen receptor gene polymorphism in Chinese Han
  women with endometriosis and endometriosis-related infertility. *Reprod. Biomed. Online* 26, 93–98 (2013).
- 49. Mafra, F., Catto, M., Bianco, B., Barbosa, C. P. & Christofolini, D. Association of WNT4
  polymorphisms with endometriosis in infertile patients. *J. Assist. Reprod. Genet.* 32, 1359–
  1364 (2015).
- 1132 50. Osiński, M. *et al.* The assessment of GWAS identified polymorphisms associated with infertility risk in Polish women with endometriosis. *Ginekol. Pol.* **89**, 304–310 (2018).
- 1134 51. Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from polygenicity
   in genome-wide association studies. *Nat. Genet.* 47, 291–295 (2015).
- 1136 52. International HapMap 3 Consortium *et al.* Integrating common and rare genetic variation in diverse human populations. *Nature* 467, 52–58 (2010).
- 1138 53. Neale lab round 2 GWAS blogpost. http://www.nealelab.is/blog/2019/10/24/updating-snp-1139 heritability-results-from-4236-phenotypes-in-uk-biobank.
- 1140 54. Dempster, E. R. & Lerner, I. M. Heritability of Threshold Characters. *Genetics* **35**, 212–236 (1950).
- 55. Tropf, F. C. *et al.* Human fertility, molecular genetics, and natural selection in modern societies. *PLoS One* **10**, e0126821 (2015).
- 56. Field, Y. *et al.* Detection of human adaptation during the past 2000 years. *Science* 354, 760–764 (2016).
- 1146 57. Mathieson, I. *et al.* Genome-wide patterns of selection in 230 ancient Eurasians. *Nature*1147 **528**, 499–503 (2015).
- 1148 58. Grossman, S. R. *et al.* Identifying recent adaptations in large-scale genomic data. *Cell* **152**, 1149 703–713 (2013).
- 59. Siewert, K. M. & Voight, B. F. BetaScan2: Standardized Statistics to Detect Balancing
  Selection Utilizing Substitution Data. *Genome Biol. Evol.* **12**, 3873–3877 (2020).
- 1152 60. Dobzhansky, T. A review of some fundamental concepts and problems of population 1153 genetics. *Cold Spring Harb. Symp. Quant. Biol.* **20**, 1–15 (1955).
- 1154 61. Lewontin, R. C. The Units of Selection. *Annu. Rev. Ecol. Syst.* **1**, 1–18 (1970).
- 1155 62. Welter, D. *et al.* The NHGRI GWAS Catalog, a curated resource of SNP-trait associations.
   1156 *Nucleic Acids Res.* 42, D1001–6 (2014).
- Rytinki, M. *et al.* Dynamic SUMOylation is linked to the activity cycles of androgen receptor
  in the cell nucleus. *Mol. Cell. Biol.* **32**, 4195–4205 (2012).
- 1159 64. Terashima, R., Tani, T., Sakakibara, K., Kurusu, S. & Kawaminami, M. Thyrotropin1160 releasing hormone stimulates NR4A3 expression in the pituitary thyrotrophs of proestrus
  1161 rats. *Endocr. J.* 70, 805–814 (2023).
- 1162
  65. Fernandez, P. M. *et al.* Nuclear receptors Nor1 and NGFI-B/Nur77 play similar, albeit distinct, roles in the hypothalamo-pituitary-adrenal axis. *Endocrinology* 141, 2392–2400 (2000).
- 1165
  1166
  1166
  1166
  1167
  1167
  1168
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167
  1167</l
- 1168 67. Pulit, S. L. *et al.* Meta-analysis of genome-wide association studies for body fat distribution 1169 in 694 649 individuals of European ancestry. *Hum. Mol. Genet.* **28**, 166–174 (2019).
- 1170 68. Kichaev, G. *et al.* Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
  1171 Am. J. Hum. Genet. **104**, 65–75 (2019).
- 1172 69. Mountjoy, E. *et al.* An open approach to systematically prioritize causal variants and genes 1173 at all published human GWAS trait-associated loci. *Nat. Genet.* **53**, 1527–1533 (2021).
- 1174 70. Ghoussaini, M. *et al.* Open Targets Genetics: systematic identification of trait-associated
   1175 genes using large-scale genetics and functional genomics. *Nucleic Acids Res.* 49, D1311–

- 1176 D1320 (2021).
- 1177 71. Nguidjoe, E. *et al.* Heterozygous inactivation of the Na/Ca exchanger increases glucose-1178 induced insulin release,  $\beta$ -cell proliferation, and mass. *Diabetes* **60**, 2076–2085 (2011).
- 1179 72. Pers, T. H. *et al.* Biological interpretation of genome-wide association studies using predicted gene functions. *Nat. Commun.* **6**, 5890 (2015).
- 1181 73. Martinez, G. & Garcia, C. Sexual selection and sperm diversity in primates. *Mol. Cell.* 1182 *Endocrinol.* 518, 110974 (2020).
- 1183
  1184
  1184
  1184
  1185
  1185
  1185
  1186
  1187
  1186
  1187
  1188
  1189
  1189
  1189
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180</l
- 1186
  1187
  1187
  1187
  1188
  1188
  1188
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180
  1180</l
- 1189 76. Ishikawa, K. *et al.* An autosomal dominant cerebellar ataxia linked to chromosome 16q22.1
  1190 is associated with a single-nucleotide substitution in the 5' untranslated region of the gene encoding a protein with spectrin repeat and Rho guanine-nucleotide exchange-factor
  1192 domains. *Am. J. Hum. Genet.* **77**, 280–296 (2005).
- 1193 77. Holmes, G. AN ATTEMPT TO CLASSIFY CEREBELLAR DISEASE, WITH A NOTE ON 1194 MARIE'S HEREDITARY CEREBELLAR ATAXIA. *Brain* **30**, 545–567 (1908).
- 1195
  78. Seminara, S. B., Acierno, J. S., Jr, Abdulwahid, N. A., Crowley, W. F., Jr & Margolin, D. H.
  1196
  1197
  1197
  1197
  1198
  (2002).
- 1199 79. Lawsón, A. J. *et al.* Cortisone-reductase deficiency associated with heterozygous mutations
  in 11beta-hydroxysteroid dehydrogenase type 1. *Proc. Natl. Acad. Sci. U. S. A.* **108**, 4111–
  1201 4116 (2011).
- 1202 80. Draper, N. *et al.* Mutations in the genes encoding 11beta-hydroxysteroid dehydrogenase
  1203 type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase
  1204 deficiency. *Nat. Genet.* 34, 434–439 (2003).
- 1205 81. Durocher, F., Morissette, J., Labrie, Y., Labrie, F. & Simard, J. Mapping of the HSD17B2
  1206 gene encoding type II 17 beta-hydroxysteroid dehydrogenase close to D16S422 on
  1207 chromosome 16q24.1-q24.2. *Genomics* 25, 724–726 (1995).
- 1208
  1209
  1209
  1209
  1209
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210
  1210</
- 1211 83. Le Quesne Stabej, P. *et al.* STAG3 truncating variant as the cause of primary ovarian 1212 insufficiency. *Eur. J. Hum. Genet.* **24**, 135–138 (2016).
- 1213 84. Caburet, S. *et al.* Mutant cohesin in premature ovarian failure. *N. Engl. J. Med.* **370**, 943–
  1214 949 (2014).
- 1215 85. Day, F. R. *et al.* Physical and neurobehavioral determinants of reproductive onset and success. *Nat. Genet.* 48, 617–623 (2016).
- 1217 86. Pasman, J. A. *et al.* The CADM2 Gene and Behavior: A Phenome-Wide Scan in UK-1218 Biobank. *Behav. Genet.* **52**, 306–314 (2022).
- 1219 87. Mills, M. C. *et al.* Identification of 371 genetic variants for age at first sex and birth linked to 1220 externalising behaviour. *Nat Hum Behav* **5**, 1717–1730 (2021).
- 1221 88. Gunnarsson, B. *et al.* A sequence variant associating with educational attainment also affects childhood cognition. *Sci. Rep.* **6**, 36189 (2016).
- 1223 89. Okbay, A. *et al.* Genome-wide association study identifies 74 loci associated with 1224 educational attainment. *Nature* **533**, 539–542 (2016).
- 1225 90. de Ziegler, D., Borghese, B. & Chapron, C. Endometriosis and infertility: pathophysiology
  1226 and management. *Lancet* 376, 730–738 (2010).

- 1227 91. Day, F. *et al.* Large-scale genome-wide meta-analysis of polycystic ovary syndrome
  1228 suggests shared genetic architecture for different diagnosis criteria. *PLoS Genet.* 14, e1007813 (2018).
- 1230 92. Tyrmi, J. S. *et al.* Leveraging Northern European population history: novel low-frequency variants for polycystic ovary syndrome. *Hum. Reprod.* **37**, 352–365 (2022).
- 1232 93. Crosignani, P. G., Bianchedi, D., Riccaboni, A. & Vegetti, W. Management of anovulatory
  1233 infertility. *Hum. Reprod.* 14 Suppl 1, 108–119 (1999).
- 1234 94. Gambineri, A. *et al.* Female infertility: which role for obesity? *Int J Obes Suppl* **9**, 65–72 (2019).
- 1236 95. Maheshwari, A., Stofberg, L. & Bhattacharya, S. Effect of overweight and obesity on
  1237 assisted reproductive technology--a systematic review. *Hum. Reprod. Update* 13, 433–444
  1238 (2007).
- 1239 96. Gaskins, A. J. Recent advances in understanding the relationship between long- and short-1240 term weight change and fertility. *F1000Res.* **7**, (2018).
- 1241 97. Zirkin, B. R. & Papadopoulos, V. Leydig cells: formation, function, and regulation. *Biol.* 1242 *Reprod.* **99**, 101–111 (2018).
- 1243 98. Burger, H. G. Androgen production in women. *Fertil. Steril.* **77 Suppl 4**, S3–5 (2002).
- 1244 99. Fortune, J. E. & Armstrong, D. T. Androgen production by theca and granulosa isolated 1245 from proestrous rat follicles. *Endocrinology* **100**, 1341–1347 (1977).
- 1246 100.Liu, Y. X. & Hsueh, A. J. Synergism between granulosa and theca-interstitial cells in 1247 estrogen biosynthesis by gonadotropin-treated rat ovaries: studies on the two-cell, two-1248 gonadotropin hypothesis using steroid antisera. *Biol. Reprod.* **35**, 27–36 (1986).
- 101. Wen, X., Li, D., Tozer, A. J., Docherty, S. M. & Iles, R. K. Estradiol, progesterone,
   testosterone profiles in human follicular fluid and cultured granulosa cells from luteinized
   pre-ovulatory follicles. *Reprod. Biol. Endocrinol.* 8, 117 (2010).
- 1252 102.Kinnear, H. M. *et al.* The ovarian stroma as a new frontier. *Reproduction* **160**, R25–R39 (2020).
- 103. Samimi, M. *et al.* The Effects of Synbiotic Supplementation on Metabolic Status in Women
   With Polycystic Ovary Syndrome: a Randomized Double-Blind Clinical Trial. *Probiotics* Antimicrob. Proteins 11, 1355–1361 (2019).
- 1257 104.Zhou, Y., Ding, X. & Wei, H. Reproductive immune microenvironment. *J. Reprod. Immunol.* 1258 **152**, 103654 (2022).
- 1259 105.Rüder, C. *et al.* The tumor-associated antigen EBAG9 negatively regulates the cytolytic 1260 capacity of mouse CD8+ T cells. *J. Clin. Invest.* **119**, 2184–2203 (2009).
- 106.Basta, P. *et al.* The immunohistochemical analysis of RCAS1, HLA-G, and B7H4-positive
   macrophages in partial and complete hydatidiform mole in both applied therapeutic surgery
   and surgery followed by chemotherapy. *Am. J. Reprod. Immunol.* 65, 164–172 (2011).
- 1264 107. Mbatchou, J. *et al.* Computationally efficient whole-genome regression for quantitative and 1265 binary traits. *Nat. Genet.* **53**, 1097–1103 (2021).
- 108.Zhou, W. *et al.* Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies. *Nat. Genet.* **50**, 1335–1341 (2018).
- 109. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* 26, 2190–2191 (2010).
- 1270 110.Benonisdottir, S. *et al.* Epigenetic and genetic components of height regulation. *Nat.* 1271 *Commun.* 7, 13490 (2016).
- 1272 111. Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA: a tool for genome-wide 1273 complex trait analysis. *Am. J. Hum. Genet.* **88**, 76–82 (2011).
- 1274 112.1000 Genomes Project Consortium *et al.* A global reference for human genetic variation.
   1275 Nature **526**, 68–74 (2015).
- 1276 113.Schaffner, S. F. The X chromosome in population genetics. *Nat. Rev. Genet.* **5**, 43–51 (2004).

- 1278 114. Veeramah, K. R. & Novembre, J. Demographic events and evolutionary forces shaping
   1279 European genetic diversity. *Cold Spring Harb. Perspect. Biol.* 6, a008516 (2014).
- 1280 115.Hinch, A. G., Altemose, N., Noor, N., Donnelly, P. & Myers, S. R. Recombination in the 1281 human Pseudoautosomal region PAR1. *PLoS Genet.* **10**, e1004503 (2014).
- 1282 116.Creators Brendan Bulik-Sullivan hilaryfinucane rkwalters Tim Poterba stevengazal
   1283 Oleksandr Frei1 Duncan Palmer Show affiliations 1. University of Oslo. *astheeggeggs/ldsc:* 1284 *ldsc rg vector*. doi:10.5281/zenodo.10497662.
- 1285 117.Gallagher, C. S. *et al.* Genome-wide association and epidemiological analyses reveal
   1286 common genetic origins between uterine leiomyomata and endometriosis. *Nat. Commun.* 1287 10, 4857 (2019).
- 1288 118.Hemani, G. *et al.* The MR-Base platform supports systematic causal inference across the 1289 human phenome. *Elife* **7**, (2018).
- 119. Burgess, S., Thompson, S. G. & CRP CHD Genetics Collaboration. Avoiding bias from
  weak instruments in Mendelian randomization studies. *Int. J. Epidemiol.* 40, 755–764
  (2011).
- 1293 120.Locke, A. E. *et al.* Genetic studies of body mass index yield new insights for obesity 1294 biology. *Nature* **518**, 197–206 (2015).
- 1295 121.Hartwig, F. P., Tilling, K., Davey Smith, G., Lawlor, D. A. & Borges, M. C. Bias in two1296 sample Mendelian randomization when using heritable covariable-adjusted summary
  1297 associations. *Int. J. Epidemiol.* **50**, 1639–1650 (2021).
- 1298 122.Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid
  instruments: effect estimation and bias detection through Egger regression. *Int. J.*1300 *Epidemiol.* 44, 512–525 (2015).
- 1301 123.Bowden, J., Davey Smith, G., Haycock, P. C. & Burgess, S. Consistent Estimation in
  1302 Mendelian Randomization with Some Invalid Instruments Using a Weighted Median
  1303 Estimator. *Genet. Epidemiol.* 40, 304–314 (2016).
- 1304 124. Giambartolomei, C. *et al.* Bayesian test for colocalisation between pairs of genetic
   1305 association studies using summary statistics. *PLoS Genet.* **10**, e1004383 (2014).
- 1306 125. Wallace, C. Eliciting priors and relaxing the single causal variant assumption in colocalisation analyses. *PLoS Genet.* **16**, e1008720 (2020).
- 1308 126.Schmiedel, B. J. *et al.* COVID-19 genetic risk variants are associated with expression of 1309 multiple genes in diverse immune cell types. *Nat. Commun.* **12**, 6760 (2021).
- 127. Finucane, H. K. *et al.* Partitioning heritability by functional annotation using genome-wide
   association summary statistics. *Nat. Genet.* 47, 1228–1235 (2015).
- 1312 128. Finucane, H. K. *et al.* Heritability enrichment of specifically expressed genes identifies
  1313 disease-relevant tissues and cell types. *Nat. Genet.* **50**, 621–629 (2018).
- 1314 129.Fan, X. *et al.* Single-cell reconstruction of follicular remodeling in the human adult ovary.
   1315 *Nat. Commun.* **10**, 3164 (2019).
- 1316
   130.Jin, C. *et al.* The regulatory landscapes of human ovarian ageing. *bioRxiv* (2022)

   1317
   doi:10.1101/2022.05.18.492547.
- 1318 131.Stuart, T. *et al.* Comprehensive Integration of Single-Cell Data. *Cell* **177**, 1888–1902.e21
   (2019).
- 132. Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell
  transcriptomic data across different conditions, technologies, and species. *Nat. Biotechnol.*36, 411–420 (2018).
- 1323 133.Satija, R., Farrell, J. A., Gennert, D., Schier, A. F. & Regev, A. Spatial reconstruction of 1324 single-cell gene expression data. *Nat. Biotechnol.* **33**, 495–502 (2015).
- 1325 134. Martin, F. J. et al. Ensembl 2023. Nucleic Acids Res. 51, D933–D941 (2023).
- 1326 135.Karczewski, K. J. *et al.* Systematic single-variant and gene-based association testing of
   1327 thousands of phenotypes in 394,841 UK Biobank exomes. *Cell Genom* 2, 100168 (2022).
- 1328 136.McLaren, W. et al. The Ensembl Variant Effect Predictor. Genome Biol. 17, 122 (2016).

- 1329 137.Karczewski, K. J. *et al.* The mutational constraint spectrum quantified from variation in 1330 141,456 humans. *Nature* **581**, 434–443 (2020).
- 1331 138.Liu, X., Li, C., Mou, C., Dong, Y. & Tu, Y. dbNSFP v4: a comprehensive database of
   1332 transcript-specific functional predictions and annotations for human nonsynonymous and
   1333 splice-site SNVs. *Genome Med.* **12**, 103 (2020).
- 1334 139. Rentzsch, P., Witten, D., Cooper, G. M., Shendure, J. & Kircher, M. CADD: predicting the
  1335 deleteriousness of variants throughout the human genome. *Nucleic Acids Res.* 47, D886–
  1336 D894 (2019).
- 1337 140. Ioannidis, N. M. *et al.* REVEL: An Ensemble Method for Predicting the Pathogenicity of 1338 Rare Missense Variants. *Am. J. Hum. Genet.* **99**, 877–885 (2016).
- 1339 141.*vep105\_loftee*. (Github).
- 1340 142. Jaganathan, K. *et al.* Predicting Splicing from Primary Sequence with Deep Learning. *Cell* 1341 **176**, 535–548.e24 (2019).
- 1342 143.Morales, J. *et al.* A joint NCBI and EMBL-EBI transcript set for clinical genomics and 1343 research. *Nature* **604**, 310–315 (2022).
- 1344 144.Richards, S. *et al.* Standards and guidelines for the interpretation of sequence variants: a
   1345 joint consensus recommendation of the American College of Medical Genetics and
   1346 Genomics and the Association for Molecular Pathology. *Genet. Med.* **17**, 405–424 (2015).
- 1347 145.Chang, C. C. *et al.* Second-generation PLINK: rising to the challenge of larger and richer
   1348 datasets. *Gigascience* 4, 7 (2015).
- 1349 146.Liu, Y. & Xie, J. Cauchy combination test: a powerful test with analytic p-value calculation 1350 under arbitrary dependency structures. *J. Am. Stat. Assoc.* **115**, 393–402 (2020).
- 147. Kivisild, T. *et al.* Patterns of genetic connectedness between modern and medieval
  1352 Estonian genomes reveal the origins of a major ancestry component of the Finnish
  1353 population. *Am. J. Hum. Genet.* **108**, 1792–1806 (2021).
- 1354 148.Su, W. *et al.* Role of HSD17B13 in the liver physiology and pathophysiology. *Mol. Cell.* 1355 *Endocrinol.* **489**, 119–125 (2019).
- 1356 149. Tardif, S. *et al.* Zonadhesin is essential for species specificity of sperm adhesion to the egg 1357 zona pellucida. *J. Biol. Chem.* **285**, 24863–24870 (2010).
- 1358 150.Fry, A. *et al.* Comparison of Sociodemographic and Health-Related Characteristics of UK
  1359 Biobank Participants With Those of the General Population. *Am. J. Epidemiol.* 186, 1026–
  1034 (2017).
- 1361 151.Fertility treatment 2021: preliminary trends and figures. https://www.hfea.gov.uk/about-1362 us/publications/research-and-data/fertility-treatment-2021-preliminary-trends-and-figures/.
- 1363 152.Leitsalu, L. *et al.* Cohort Profile: Estonian Biobank of the Estonian Genome Center, 1364 University of Tartu. *Int. J. Epidemiol.* **44**, 1137–1147 (2015).
- 1365 153.Sørensen, E. *et al.* Data Resource Profile: The Copenhagen Hospital Biobank (CHB). *Int. J.* 1366 *Epidemiol.* **50**, 719–720e (2021).
- 1367 154. Nisbett, R. E. *et al.* Intelligence: new findings and theoretical developments. *Am. Psychol.*1368 **67**, 130–159 (2012).
- 1369 155.Rask-Andersen, M., Karlsson, T., Ek, W. E. & Johansson, Å. Modification of Heritability for
  1370 Educational Attainment and Fluid Intelligence by Socioeconomic Deprivation in the UK
  1371 Biobank. *Am. J. Psychiatry* **178**, 625–634 (2021).
- 1372 156.Balbo, N., Billari, F. C. & Mills, M. Fertility in Advanced Societies: A Review of Research: La fécondité dans les sociétés avancées: un examen des recherches. *Eur. J. Popul.* 29, 1–38 (2013).
- 1375 157.Petersen, B.-S., Fredrich, B., Hoeppner, M. P., Ellinghaus, D. & Franke, A. Opportunities
   1376 and challenges of whole-genome and -exome sequencing. *BMC Genet.* 18, 14 (2017).
- 1377 158.Park, J.-H. *et al.* Distribution of allele frequencies and effect sizes and their
  1378 interrelationships for common genetic susceptibility variants. *Proc. Natl. Acad. Sci. U. S. A.*1379 108. 18026–18031 (2011).

- 1380 159.Ruth, K. S. *et al.* Using human genetics to understand the disease impacts of testosterone
  1381 in men and women. *Nat. Med.* 26, 252–258 (2020).
- 1382 160. Tchernof, A. *et al.* Androgens and the Regulation of Adiposity and Body Fat Distribution in 1383 Humans. *Compr. Physiol.* **8**, 1253–1290 (2018).
- 1384 161.Loh, N. Y. *et al.* Sex hormones, adiposity, and metabolic traits in men and women: a
  1385 Mendelian randomisation study. *Eur. J. Endocrinol.* **186**, 407–416 (2022).
- 1386 162.Palmer, B. F. & Clegg, D. J. The sexual dimorphism of obesity. *Mol. Cell. Endocrinol.* 402, 113–119 (2015).
- 1388 163.Schulze, M. B. & Stefan, N. Genetic Predisposition to Abdominal Adiposity and
  1389 Cardiometabolic Risk. *JAMA: the journal of the American Medical Association* vol. 317
  1390 2334 (2017).
- 1391 164. Goossens, G. H., Jocken, J. W. E. & Blaak, E. E. Sexual dimorphism in cardiometabolic
  1392 health: the role of adipose tissue, muscle and liver. *Nat. Rev. Endocrinol.* **17**, 47–66 (2021).
- 1393 165.Agarwal, A., Mulgund, A., Hamada, A. & Chyatte, M. R. A unique view on male infertility 1394 around the globe. *Reprod. Biol. Endocrinol.* **13**, 37 (2015).
- 1395 166.Sudlow, C. *et al.* UK biobank: an open access resource for identifying the causes of a wide 1396 range of complex diseases of middle and old age. *PLoS Med.* **12**, e1001779 (2015).
- 1397 167.Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data.
   1398 *Nature* 562, 203–209 (2018).
- 1399 168.Zhang, D., Dey, R. & Lee, S. Fast and robust ancestry prediction using principal component analysis. *Bioinformatics* 36, 3439–3446 (2020).
- 1401 169.Dey, R. & Lee, S. Asymptotic properties of principal component analysis and shrinkage1402 bias adjustment under the generalized spiked population model. *J. Multivar. Anal.* 173,
  1403 145–164 (2019).
- 1404 170.randomForest: Breiman and Cutler's Random Forests for Classification and Regression.
   1405 *Comprehensive R Archive Network (CRAN)* https://cran.r 1406 project.org/web/packages/randomForest.
- 1407 171.Fraser, A. *et al.* Cohort Profile: the Avon Longitudinal Study of Parents and Children:
   1408 ALSPAC mothers cohort. *Int. J. Epidemiol.* 42, 97–110 (2013).
- 1409 172.McCarthy, S. *et al.* A reference panel of 64,976 haplotypes for genotype imputation. *Nat.*1410 *Genet.* 48, 1279–1283 (2016).
- 1411 173.Loh, P.-R. *et al.* Efficient Bayesian mixed-model analysis increases association power in large cohorts. *Nat. Genet.* 47, 284–290 (2015).
- 174. Hansen, T. F. *et al.* DBDS Genomic Cohort, a prospective and comprehensive resource for
  integrative and temporal analysis of genetic, environmental and lifestyle factors affecting
  health of blood donors. *BMJ Open* **9**, e028401 (2019).
- 1416 175.Kong, A. *et al.* Detection of sharing by descent, long-range phasing and haplotype
  1417 imputation. *Nat. Genet.* 40, 1068–1075 (2008).
- 1418 176.Gudbjartsson, D. F. *et al.* Large-scale whole-genome sequencing of the Icelandic population. *Nat. Genet.* 47, 435–444 (2015).
- 1420 177.Reisberg, S. *et al.* Translating genotype data of 44,000 biobank participants into clinical
  1421 pharmacogenetic recommendations: challenges and solutions. *Genet. Med.* 21, 1345–1354
  1422 (2019).
- 1423 178. Finer, S. *et al.* Cohort Profile: East London Genes & Health (ELGH), a community-based
  1424 population genomics and health study in British Bangladeshi and British Pakistani people.
  1425 *Int. J. Epidemiol.* 49, 20–21i (2020).
- 1426 179. Taliun, D. *et al.* Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program.
  1427 *Nature* 590, 290–299 (2021).
- 1428 180.Suhre, K. *et al.* Connecting genetic risk to disease end points through the human blood plasma proteome. *Nat. Commun.* **8**, 14357 (2017).
- 1430 181. Dennis, J. K. *et al.* Clinical laboratory test-wide association scan of polygenic scores

- identifies biomarkers of complex disease. *Genome Med.* **13**, 6 (2021).
- 1432 182. Thareja, G. *et al.* Differences and commonalities in the genetic architecture of protein
  1433 quantitative trait loci in European and Arab populations. *Hum. Mol. Genet.* 32, 907–916
  1434 (2023).
- 1435 183.Pott, J. *et al.* Genetic Association Study of Eight Steroid Hormones and Implications for
  1436 Sexual Dimorphism of Coronary Artery Disease. *J. Clin. Endocrinol. Metab.* 104, 5008–
  1437 5023 (2019).
- 1438 184.Prins, B. P. *et al.* Genome-wide analysis of health-related biomarkers in the UK Household 1439 Longitudinal Study reveals novel associations. *Sci. Rep.* **7**, 11008 (2017).
- 1440 185.Kuhn, R. M., Haussler, D. & Kent, W. J. The UCSC genome browser and associated tools.
  1441 Brief. Bioinform. 14, 144–161 (2013).
- 1442 186.hail 0.2 documentation. https://hail.is/docs/0.2/.